<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>OLANZAPINE AND FLUOXETINE- olanzapine and fluoxetine hydrochloride capsule </strong><br>Par Pharmaceutical, Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Olanzapine and Fluoxetine Capsules USP safely and effectively. See full prescribing information for Olanzapine and Fluoxetine Capsules USP. <br>Olanzapine and Fluoxetine Capsules USP for oral use.<br>Initial U.S. Approval: 2003 </div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS AND INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<h1 class="Warning">See full prescribing information for complete boxed warning.</h1>
<dl>
<dt>•</dt>
<dd>Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) and other psychiatric disorders. Olanzapine and Fluoxetine Hydrochloride is not approved for use in children and adolescents (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>, <a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>, <a href="#inv-ab2079cd-cd6f-4464-9a6e-8b636edf1a63">17.2</a>). </dd>
<dt>•</dt>
<dd>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine and Fluoxetine Hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>, <a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>, <a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>).</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Dosage and Administration</span>: </p>
<p class="Highlighta">Specific Populations (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)                                                                                             01/2013 </p>
<p class="Highlighta">Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) </p>
<p class="Highlighta">Intended to Treat Psychiatric Disorders (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>)                                                               01/2013 </p>
<p class="Highlighta">Use of Olanzapine and Fluoxetine Capsules with other MAOIs such </p>
<p class="Highlighta"> as Linezolid or  Methylene Blue (<a href="#ID_27db6d82-35cd-467d-b7c8-7c21ff488e83">2.5</a>)                                                                        01/2013 </p>
<p class="Highlighta"><span class="Bold">Contraindications:</span> </p>
<p class="Highlighta">Monoamine Oxidase Inhibitors (MAOIs) (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>)                                                           01/2013 </p>
<p class="Highlighta">Other Contraindications (<a href="#ID_5a2ed202-e431-4f0f-8b97-18f22811ccb6">4.2</a>)                                                                                      01/2013 </p>
<p class="Highlighta"><span class="Bold">Warnings and Precautions:</span> </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">(5.7</a>)                                                                                           01/2013 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS AND INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></h1>
<h1 class="Warning">See full prescribing information for complete boxed warning.</h1>
<dl>
<dt>•</dt>
<dd>Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) and other psychiatric disorders. Olanzapine and Fluoxetine Hydrochloride is not approved for use in children and adolescents (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>, <a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>, <a href="#inv-ab2079cd-cd6f-4464-9a6e-8b636edf1a63">17.2</a>). </dd>
<dt>•</dt>
<dd>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine and Fluoxetine Hydrochloride is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>, <a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>, <a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>).</dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Olanzapine and fluoxetine capsules combines olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of: </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> in adults (<a href="#inv-7e1465cc-5f1b-4884-a657-c972a6ccf2d5">1.1</a>)</dd>
</dl>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Once daily in the evening, generally beginning with 6 mg/25 mg (<a href="#inv-2adabc93-c416-4ec9-9b14-1d043bca7797">2.1</a>)</dd>
<dt>•</dt>
<dd>The starting dose of Olanzapine and Fluoxetine Capsules 3 mg/25 mg – 6 mg/25 mg should be used in patients predisposed to hypotensive reactions, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or with potential for slowed metabolism. Escalate dose cautiously (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)</dd>
<dt>•</dt>
<dd>Consider tapering the dose of fluoxetine for pregnant women during the third trimester (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)</dd>
<dt>•</dt>
<dd>Discontinue gradually (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>)</dd>
<dt>•</dt>
<dd>The safety of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical trials (<a href="#inv-2adabc93-c416-4ec9-9b14-1d043bca7797">2.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Capsules: 3 mg/25 mg, 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, and 12 mg/50 mg (mg equivalent olanzapine/mg equivalent fluoxetine) (<a href="#inv-d7487617-5989-4fb1-9165-7d12b062c093">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with Olanzapine and Fluoxetine Capsules or within 5 weeks of stopping treatment with Olanzapine and Fluoxetine Capsules. Do not use Olanzapine and Fluoxetine Capsules withing 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start Olanzapine and Fluoxetine Capsules in a patient who is being treated with linezolid or intravenous methylene blue. (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>)</dd>
<dt>•</dt>
<dd> Do not use with pimozide due to risk of drug interaction or Q<span class="Sub">Tc</span> prolongation (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>, <a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>Do not use with thioridazine due to QT<span class="Sub">c</span> interval prolongation or potential for elevated thioridazine plasma levels. Do not use thioridazine within 5 weeks of discontinuing olanzapine and fluoxetine hydrochloride (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>, <a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk: </span>Monitor for clinical worsening and suicidal thinking and behavior (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: </span>Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>: </span>Manage with immediate discontinuation and close monitoring (<a href="#inv-7fe11f74-884b-4d48-9bfb-8dba19ebc1a0">5.3</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>: </span>In some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients taking olanzapine. Patients taking olanzapine and fluoxetine hydrochloride should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and undergo fasting blood glucose testing at the beginning of, and periodically during, treatment. (<a href="#inv-d8179809-2795-4eff-a8f1-796f6db0940a">5.4</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span>: </span>Undesirable alterations in lipids have been observed. Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically during, treatment (<a href="#inv-8bcdf333-e6c5-41cc-9c8a-bc83f4a66973">5.5</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>: </span>Potential consequences of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be considered. Patients should receive regular monitoring of weight (<a href="#inv-c82e5c02-0ff3-4459-bf36-bcc21c54d8a4">5.6</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>:</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> has been reported with SSRIs and SNRIs, including Olanzapine and fluoxetine capsules, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John’s Wort). If such symptoms occur, discontinue Olanzapine and fluoxetine capsules and initiate supportive treatment. If concomitant use of Olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>).<span class="Italics"></span>
</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>: </span>Discontinue upon appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or allergic phenomena (<a href="#inv-f9bf1ec3-d4d7-4c6a-b32e-8857b18039a6">5.8</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span>: </span>Screen for Bipolar Disorder and monitor for activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> (<a href="#inv-9040c9ad-a5b3-4c8b-b186-9b95492ada13">5.9</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>: </span>Discontinue if clinically appropriate (<a href="#inv-7ba4bd83-7da8-4d96-a82d-16f449dd9571">5.10</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>: </span><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and, in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, may occur especially during initial dose titration. Use caution in patients with cardiovascular disease or cerebrovascular disease, and those conditions that could affect hemodynamic responses (<a href="#inv-66597682-6f74-44e5-9c0e-69b9d506a574">5.11</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>: </span>Has been reported with antipsychotics, including olanzapine and fluoxetine hydrochloride. Patients with a history of a clinically significant low white blood cell count (WBC) or drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/ <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of olanzapine and fluoxetine hydrochloride should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors (<a href="#inv-b11644fe-433b-45a8-a30d-4f1fbc2a85bb">5.12</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: </span>Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (<a href="#inv-cb14208f-4d7d-49ed-b151-fb0894fb510c">5.14</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>: </span>May increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Use with NSAIDs, aspirin, warfarin, or drugs that affect coagulation may potentiate the risk of gastrointestinal or other <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#inv-09cc51c9-342e-45cb-9784-0429d5c0b351">5.15</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>: </span>Has been reported with olanzapine and fluoxetine hydrochloride in association with syndrome of inappropriate antidiuretic hormone (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>) (<a href="#inv-9e6d3f5a-bb88-4467-af87-c86e9acdf898">5.16</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Potential for Cognitive and Motor Impairment: </span>Has potential to impair judgment, thinking, and motor skills. Use caution when operating machinery (<a href="#inv-3dee430c-291b-4312-8599-821fed557a6c">5.17</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>: </span>May elevate prolactin levels (<a href="#inv-4a8ae178-fcff-4c9f-b980-1c8db7209182">5.20</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Long Elimination Half-Life of Fluoxetine: </span>Changes in dose will not be fully reflected in plasma for several weeks (<a href="#inv-a681d8d5-0a95-4278-83e4-886f354eacaa">5.22</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Laboratory Tests: </span>Monitor fasting blood glucose and lipid profiles at the beginning of, and periodically during, treatment (<a href="#inv-06ba434d-cd7e-44fe-a79a-11ed0e11ee05">5.24</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical Companies, Inc. 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
<p class="Highlighta">Most common adverse reactions (≥5% and at least twice that for placebo) are <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> ( <a href="#inv-f47d55bf-1a46-4360-b21f-f81aaea026cb">6.1</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Monoamine Oxidase Inhibitor (MAOI): </span><a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">(2.4</a>, <a href="#ID_27db6d82-35cd-467d-b7c8-7c21ff488e83">2.5</a>, <a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>, <a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>, <a href="#inv-0982aece-1997-4ea0-8959-9b67efb5870c">7.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Pimozide: </span>Olanzapine and fluoxetine hydrochloride is contraindicated for use with pimozide due to risk of risk of drug interaction or QT<span class="Sub">c</span> prolongation (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>, <a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Thioridazine: </span>Olanzapine and fluoxetine hydrochloride is contraindicated for use with thioridazine due to QT<span class="Sub">c</span> interval prolongation or potential for elevated thioridazine plasma levels. Do not use thioridazine within 5 weeks of discontinuing olanzapine and fluoxetine hydrochloride (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>, <a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Drugs Metabolized by CYP2D6: </span>Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Tricyclic Antidepressants (TCAs): </span>Monitor TCA levels during coadministration with olanzapine and fluoxetine hydrochloride or when olanzapine and fluoxetine hydrochloride has been recently discontinued (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7,</a><a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">CNS Acting Drugs: </span>Caution is advised if the concomitant administration of olanzapine and fluoxetine hydrochloride and other CNS-active drugs is required (<a href="#inv-6884cf9d-6a91-4313-bd1d-19931593879e">7.2</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Antihypertensive Agent: </span>Enhanced antihypertensive effect (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Levodopa and Dopamine Agonists: </span>May antagonize levodopa/dopamine agonists (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Benzodiazepines: </span>May potentiate <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and sedation (<a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6</a>, <a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Clozapine: </span>May elevate clozapine levels (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Haloperidol: </span>Elevated haloperidol levels have been observed (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Carbamazepine: </span>Potential for elevated carbamazepine levels and clinical <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">anticonvulsant toxicity</span> (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Phenytoin: </span>Potential for elevated phenytoin levels and clinical <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">anticonvulsant toxicity</span> (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Alcohol: </span>May potentiate sedation and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Serotonergic Drugs: </span>(<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4,</a><a href="#ID_27db6d82-35cd-467d-b7c8-7c21ff488e83">2.5</a>, <a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>, <a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Fluvoxamine: </span>May increase olanzapine levels; a lower dose of the olanzapine component of olanzapine and fluoxetine hydrochloride should be considered (<a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin, etc.): </span>May potentiate the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#inv-6f7af79a-238e-4967-b17d-4a0fe651255d">7.4</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Drugs Tightly Bound to Plasma Proteins: </span>Fluoxetine may cause shift in plasma concentrations (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>
<span class="Italics">Pregnancy: </span>Olanzapine and fluoxetine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (<a href="#inv-5a072cea-4133-49ad-b1d5-5efb495ce19f">8.1</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics">Nursing Mothers: </span>Breast feeding is not recommended (<a href="#inv-d9a8afb7-28df-4930-b228-7c2e43925ffe">8.3</a>) </dd>
<dt>•</dt>
<dd>
<span class="Italics">Pediatric Use: </span>Safety and effectiveness of olanzapine and fluoxetine hydrochloride in children and adolescent patients have not been established (<a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>)</dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>Use a lower or less frequent dose in patients with cirrhosis (<a href="#inv-f94d8c73-26be-46d4-a323-00d45eac781e">8.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 2/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING </a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </a></h2>
<h2><a href="#section-2.2" class="toc">2.3 Specific Populations </a></h2>
<h2><a href="#section-2.3" class="toc">2.4 Switching a Patient To or From a Monamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</a></h2>
<h2><a href="#section-2.4" class="toc">2.5 Use of Olanzapine and Fluoxetine Capsules with Other MAOIs such as Linezolid or Methylene Blue</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Other Containdications</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </a></h2>
<h2><a href="#section-5.16" class="toc">5.16 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Potential for Cognitive and Motor Impairment </a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Body Temperature Regulation </a></h2>
<h2><a href="#section-5.19" class="toc">5.19 Use in Patients with Concomitant Illness </a></h2>
<h2><a href="#section-5.20" class="toc">5.20 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> </a></h2>
<h2><a href="#section-5.21" class="toc">5.21 Concomitant Use of Olanzapine and Fluoxetine Products </a></h2>
<h2><a href="#section-5.22" class="toc">5.22 Long Elimination Half-Life of Fluoxetine </a></h2>
<h2><a href="#section-5.23" class="toc">5.23 Discontinuation of Treatment with Olanzapine and Fluoxetine HCl </a></h2>
<h2><a href="#section-5.24" class="toc">5.24 Laboratory Tests </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS </a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Vital Signs and Laboratory Studies </a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS </a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors (MAOI) </a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CNS Acting Drugs </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Serotonergic Drugs </a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin) </a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Electroconvulsive Therapy (ECT)</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Potential for Other Drugs to Affect Olanzapine and Fluoxetine HCl</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Potential for Olanzapine and Fluoxetine HCl to Affect Other Drugs</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS </a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy </a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery </a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers </a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use </a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></h1>
<h2><a href="#section-9.1" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE </a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION </a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY </a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action </a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics </a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h2><a href="#section-12.4" class="toc">12.4 Specific Populations </a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY </a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES </a></h1>
<h2><a href="#section-14.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied </a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling </a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION </a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Information on Medication Guide </a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk </a></h2>
<h2><a href="#section-16.3" class="toc">17.3 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: Increased Mortality and Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) </a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </a></h2>
<h2><a href="#section-16.6" class="toc">17.6 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </a></h2>
<h2><a href="#section-16.7" class="toc">17.7 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> </a></h2>
<h2><a href="#section-16.8" class="toc">17.8 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </a></h2>
<h2><a href="#section-16.9" class="toc">17.9 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </a></h2>
<h2><a href="#section-16.10" class="toc">17.10 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </a></h2>
<h2><a href="#section-16.11" class="toc">17.11 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </a></h2>
<h2><a href="#section-16.12" class="toc">17.12 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </a></h2>
<h2><a href="#section-16.13" class="toc">17.13 Potential for Cognitive and Motor Impairment </a></h2>
<h2><a href="#section-16.14" class="toc">17.14 Body Temperature Regulation </a></h2>
<h2><a href="#section-16.15" class="toc">17.15 Concomitant Medication </a></h2>
<h2><a href="#section-16.16" class="toc">17.16 Discontinuation of Treatment with Olanzapine and Fluoxetine HCl </a></h2>
<h2><a href="#section-16.17" class="toc">17.17 Alcohol </a></h2>
<h2><a href="#section-16.18" class="toc">17.18 Use in Specific Populations </a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="inv-b5f1864a-f7a2-49c4-9eb9-2423359e9996"></a><a name="section-1"></a><p></p>
<h1>WARNING </h1>
<p class="First"><span class="Bold">SUICIDALITY AND ANTIDEPRESSANT DRUGS AND INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span> </span></p>
<p><span class="Bold">S<span class="Underline">uicidality and Antidepressant Drugs </span>— Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of Olanzapine and Fluoxetine Hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Olanzapine and Fluoxetine Hydrochloride is not approved for use in pediatric patients.<span class="Italics">[See Warnings and Precautions (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>), Use in Specific Populations (<a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>), and Patient Counseling Information (<a href="#inv-ab2079cd-cd6f-4464-9a6e-8b636edf1a63">17.2</a>)]</span>. </span></p>
<p><span class="Bold">I<span class="Underline">ncreased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> </span> — Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Olanzapine and fluoxetine HCl is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Warnings and Precautions (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>, <a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>) and Patient Counseling Information (<a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>)]</span>. </span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="inv-f82a72d9-7f97-4e1e-b47d-0f755f65d054"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-7e1465cc-5f1b-4884-a657-c972a6ccf2d5"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </h2>
<p class="First">Olanzapine and fluoxetine HCl is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> in adults <span class="Italics">[see Clinical Studies (<a href="#inv-98a01770-83bd-4544-a927-5c835e23e7e2">14.1</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="inv-0499d11a-3b8f-454d-a5ff-955a40e9a528"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2adabc93-c416-4ec9-9b14-1d043bca7797"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </h2>
<p class="First">Olanzapine and Fluoxetine Capsules should be administered once daily in the evening, generally beginning with the 6 mg/25 mg capsule. While food has no appreciable effect on the absorption of olanzapine and fluoxetine given individually, the effect of food on the absorption of olanzapine and fluoxetine HCl has not been studied. Dosage adjustments, if indicated, can be made according to efficacy and tolerability. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine HCl in a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg [see<span class="Italics"> Clinical Studies ( <a href="#inv-98a01770-83bd-4544-a927-5c835e23e7e2">14.1</a>)</span>]. The safety of doses above 18 mg per 75 mg has not been evaluated in clinical studies. </p>
<p>While there is no body of evidence to answer the question of how long a patient treated with olanzapine and fluoxetine HCl should remain on it, it is generally accepted that <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, including the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, is a chronic illness requiring chronic treatment. The physician should periodically reexamine the need for continued pharmacotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-1231bce1-bec5-4dc5-84da-2a30d42ac454"></a><a name="section-2.2"></a><p></p>
<h2>2.3 Specific Populations </h2>
<p class="First">The starting dose of Olanzapine and Fluoxetine Capsules 3 mg/25 mg to 6 mg/25 mg should be used for patients with a predisposition to hypotensive reactions, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or patients who exhibit a combination of factors that may slow the metabolism of olanzapine and fluoxetine HCl (female gender, geriatric age, nonsmoking status) or those patients who may be pharmacodynamically sensitive to olanzapine. Dosing modification may be necessary in patients who exhibit a combination of factors that may slow metabolism. When indicated, dose escalation should be performed with caution in these patients. Olanzapine and fluoxetine HCl has not been systematically studied in patients &gt;65 years of age or in patients &lt;18 years of age <span class="Italics">[see Warnings and Precautions (<a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>), Use in Specific Populations (<a href="#inv-592f745a-0a5f-4fc0-aac0-084a49716dae">8.5</a>), and Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>, <a href="#inv-8423052d-ce2b-47a2-9ef2-b47e30cb1fc4">12.4</a>)]</span>. </p>
<p><span class="Underline">Treatment of Pregnant Women </span>— When treating pregnant women with fluoxetine, a component of olanzapine and fluoxetine HCl, during the third trimester, the physician should carefully consider the potential risks and potential benefits of treatment. Neonates exposed to SSRIs or SNRIs late in the third trimester have developed complications requiring prolonged hospitalizations, respiratory support, and tube feeding. The physician may consider tapering the dose of fluoxetine in the third trimester <span class="Italics">[see Use in Specific Populations (<a href="#inv-5a072cea-4133-49ad-b1d5-5efb495ce19f">8.1</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-295990ef-2bcc-45ea-8b6f-c5d87d811633"></a><a name="section-2.3"></a><p></p>
<h2>2.4 Switching a Patient To or From a Monamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>
<p class="First">At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders, and initiation of therapy with  olanzapine and fluoxetine. Conversely, at least 5 weeks should be allowed after stopping olanzapine and fluoxetine before starting an MAOI intended to treat psychiatric disorders [see<span class="Italics"> Contraindications</span> (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27db6d82-35cd-467d-b7c8-7c21ff488e83"></a><a name="section-2.4"></a><p></p>
<h2>2.5 Use of Olanzapine and Fluoxetine Capsules with Other MAOIs such as Linezolid or Methylene Blue</h2>
<p class="First">Do not start olanzapine and fluoxetine in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see <span class="Italics">Contraindications (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>)</span>].</p>
<p>In some cases, a patient already receiving olanzapine and fluoxetine therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue are judged to outweigh the risks of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> in a particular patient, olanzapine and fluoxetine should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> for five weeks or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Olanzapine and Fluoxetine Capsules may be resumed 24 hours after the last dose of linezolid and intravenous methylene blue  [see <span class="Italics">Warning and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>)</span>].</p>
<p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1mg/kg with olanzapine and fluoxetine in unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with such use [see <span class="Italics">Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>)</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="inv-d7487617-5989-4fb1-9165-7d12b062c093"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Capsules (mg equivalent olanzapine/mg equivalent fluoxetine):</p>
<dl>
<dt>•</dt>
<dd>3 mg/25 mg</dd>
<dt>•</dt>
<dd>6 mg/25 mg</dd>
<dt>•</dt>
<dd>6 mg/50 mg</dd>
<dt>•</dt>
<dd>12 mg/25 mg</dd>
<dt>•</dt>
<dd>12 mg/50 mg</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="inv-9a42d0cc-993b-417a-b9c5-84e26819d16e"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Click here to enter text.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First">The use of  MAOIs intended to treat psychiatric disorders with olanzapine and fluoxetine or within 5 weeks of stopping treatment with olanzapine and fluoxetine is contraindicated because of an increased risk of sertotonin syndrome. The use of olanzapine and fluoxetine with  14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated. [ see <span class="Italics">Dosage and Administration (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>) and Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5a2ed202-e431-4f0f-8b97-18f22811ccb6"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Other Containdications</h2>
<p class="First">The use of olanzapine and fluoxetine is contraindicated with the following:</p>
<dl>
<dt>•</dt>
<dd>Pimozide – [see<span class="Italics"> Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</span>]</dd>
<dt>•</dt>
<dd>Thioridazine – [see <span class="Italics">Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)</span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="inv-c478cc56-2ae6-43e5-bf56-dd88ddebae1b"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-889a889d-de41-4218-8626-2763d775e8d5"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk </h2>
<p class="First">Patients with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">Obsessive Compulsive Disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug versus placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in <span class="Bold">Table 1</span>. </p>
<a name="_Refinv-9a1f73b5-910b-44ec-a968-82f55a3f"></a><table>
<caption><span>Table 1: Suicidality per 1000 Patients Treated </span></caption>
<col width="10%">
<col width="105%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"> Age Range</p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"> Drug-Placebo Difference in 	Number of Cases of Suicidality per 1000 Patients 	Treated</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"><p class="First"> Increases Compared to 	Placebo</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &lt;18 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 14 additional cases </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> 18 to 24 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 5 additional cases </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"><p class="First"> Decreases Compared to 	Placebo</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> 25 to 64 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 1 fewer case </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> ≥65 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 6 fewer cases </p></td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. </span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms <span class="Italics">[see Warnings and Precautions (<a href="#inv-9b672363-cf47-4954-99e9-869122a892c8">5.23</a>)]</span>. </p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers.</span> Prescriptions for olanzapine and fluoxetine HCl should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p>It should be noted that olanzapine and fluoxetine HCl is not approved for use in treating any indications in the pediatric population <span class="Italics">[see Use in Specifi</span>c <span class="Italics">Populations (<a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> </h2>
<p class="First"><span class="Bold">I<span class="Underline">ncreased Mortality </span></span>— <span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Olanzapine and fluoxetine HCl is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Boxed Warning</span>, <span class="Italics">Warnings and Precautions (<a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>), and Patient Counseling Information (<a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>)]</span>. </span></p>
<p>In olanzapine placebo-controlled clinical trials of elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, the incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs 1.5%, respectively).</p>
<p><span class="Underline">Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </span>— Cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with olanzapine compared to patients treated with placebo. Olanzapine and olanzapine and fluoxetine HCl are not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Boxed Warning and Patient Counseling Information (<a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-7fe11f74-884b-4d48-9bfb-8dba19ebc1a0"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) </h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including olanzapine. Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.</p>
<p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.</p>
<p>If after recovering from NMS, a patient requires treatment with an antipsychotic, the patient should be carefully monitored, since recurrences of NMS have been reported <span class="Italics">[see Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>) and Patient Counseling Information (<a href="#inv-e74c3837-25db-4c1f-947c-c86ef7138fdd">17.4</a>, <a href="#inv-afca4010-a9a3-48ba-9001-2998e6db87d8">17.8</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-d8179809-2795-4eff-a8f1-796f6db0940a"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </h2>
<p class="First">Physicians should consider the risks and benefits when prescribing olanzapine and fluoxetine HCl to patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, or having borderline increased blood glucose level (fasting 100 to 126 mg/dL, nonfasting 140 to 200 mg/dL). Patients taking olanzapine and fluoxetine HCl should be monitored regularly for worsening of glucose control. Patients starting treatment with olanzapine and fluoxetine HCl should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug <span class="Italics">[see Patient Counselin</span>g <span class="Italics">Information (<a href="#inv-5259af63-e319-46a8-9cc1-5f1125bd2e1f">17.5</a>)]</span>. </p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics, including olanzapine alone, as well as olanzapine taken concomitantly with fluoxetine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions in patients treated with the atypical antipsychotics. While relative risk estimates are inconsistent, the association between atypical antipsychotics and increases in glucose levels appears to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> on a continuum and olanzapine appears to have a greater association than some other atypical antipsychotics.</p>
<p>Mean increases in blood glucose have been observed in patients treated (median exposure of 9.2 months) with olanzapine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The mean increase of serum glucose (fasting and nonfasting samples) from baseline to the average of the 2 highest serum concentrations was 15.0 mg/dL.</p>
<p>In a study of healthy volunteers, subjects who received olanzapine (N=22) for 3 weeks had a mean increase compared to baseline in fasting blood glucose of 2.3 mg/dL. Placebo-treated subjects (N=19) had a mean increase in fasting blood glucose compared to baseline of 0.34 mg/dL.</p>
<p>In an analysis of 7 controlled clinical studies, 2 of which were placebo-controlled, with treatment duration up to 12 weeks, olanzapine and fluoxetine HCl was associated with a greater mean change in random glucose compared to placebo (8.65 mg/dL vs -3.86 mg/dL). The difference in mean changes between olanzapine and fluoxetine HCl and placebo was greater in patients with evidence of glucose dysregulation at baseline (including those patients diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or related adverse reactions, patients treated with anti-diabetic agents, patients with a baseline random glucose level ≥200 mg/dL, or a baseline fasting glucose level ≥126 mg/dL). Olanzapine and fluoxetine HCl - treated patients had a greater mean HbA <span class="Sub">1c</span> increase from baseline of 0.15% (median exposure 63 days), compared to a mean HbA<span class="Sub">1c</span> decrease of 0.04% in fluoxetine-treated subjects (median exposure 57 days) and a mean HbA<span class="Sub">1c</span> increase of 0.12% in olanzapine- treated patients (median exposure 56 days). </p>
<p>In an analysis of 6 controlled clinical studies, a larger proportion of olanzapine and fluoxetine HCl -treated subjects had <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> (4.4%) compared to placebo-treated subjects (1.4%).</p>
<p>The mean change in nonfasting glucose in patients exposed at least 48 weeks was 5.9 mg/dL (N=425).</p>
<p><span class="Bold">Table 2</span> shows short-term and long-term changes in random glucose levels from adult olanzapine and fluoxetine HCl studies. </p>
<a name="_Refinv-56cf2956-5e9d-49e9-a254-350c403f"></a><table>
<caption><span>Table 2: Changes in Random Glucose Levels from Adult Olanzapine and Fluoxetine HCl Studies</span></caption>
<col width="21%">
<col width="26%">
<col width="24%">
<col width="8%">
<col width="14%">
<col width="9%">
<col width="14%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">
<span class="Sup">a</span> Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Up to 12 weeks 	exposure</span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">At least 48 weeks 	exposure</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Laboratory 	Analyte</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Category Change (at least 	once) from Baseline</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients</span></p></td>
<td valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients</span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Random 	Glucose</p></td>
<td rowspan="2" valign="top"><p class="First"> Normal to High 	  (&lt;140 mg/dL to ≥200 mg/dL)</p></td>
<td valign="top"><p class="First"> Olanzapine and 	Fluoxetine</p></td>
<td valign="top"><p class="First"> 609</p></td>
<td valign="top"><p class="First"> 2.3%</p></td>
<td valign="top"><p class="First"> 382</p></td>
<td valign="top"><p class="First"> 3.1%</p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo</p></td>
<td valign="top"><p class="First"> 346</p></td>
<td valign="top"><p class="First"> 0.3%</p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"></td>
<td rowspan="2" valign="top"><p class="First"> Borderline to 	High (≥140 mg/dL and &lt;200 mg/dL to ≥200 	mg/dL)</p></td>
<td valign="top"><p class="First"> Olanzapine and Fluoxetine</p></td>
<td valign="top"><p class="First"> 44</p></td>
<td valign="top"><p class="First"> 34.1%</p></td>
<td valign="top"><p class="First"> 27</p></td>
<td valign="top"><p class="First"> 37.0%</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Placebo</p></td>
<td class="Botrule" valign="top"><p class="First"> 28</p></td>
<td class="Botrule" valign="top"><p class="First"> 3.6%</p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
</tbody>
</table>
<p>Controlled fasting glucose data is limited for olanzapine and fluoxetine HCl; however, in an analysis of 5 placebo-controlled olanzapine monotherapy studies with treatment duration up to 12 weeks, olanzapine was associated with a greater mean change in fasting glucose levels compared to placebo (2.76 mg/dL vs 0.17 mg/dL).</p>
<p>The mean change in fasting glucose for olanzapine-treated patients exposed at least 48 weeks was 4.2 mg/dL (N=487). In analyses of patients who completed 9 to 12 months of olanzapine therapy, mean change in fasting and nonfasting glucose levels continued to increase over time.</p>
<p><span class="Underline">Olanzapine Monotherapy in Adolescents </span>— The safety and efficacy of olanzapine and fluoxetine in combination have not been established in patients under the age of 18 years. The safety and efficacy of olanzapine have not been established in patients under the age of 13 years. In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (6 weeks) or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) (3 weeks), olanzapine was associated with a greater mean change from baseline in fasting glucose levels compared to placebo (2.68 mg/dL vs -2.59 mg/dL). The mean change in fasting glucose for adolescents exposed at least 24 weeks was 3.1 mg/dL (N=121). <span class="Bold">Table 3</span> shows short-term and long-term changes in fasting blood glucose from adolescent olanzapine monotherapy studies. </p>
<a name="_Refinv-8c713db4-253f-40a7-b411-a8e7a321"></a><table>
<caption><span>Table 3: Changes in Fasting Glucose Levels from Adolescent Olanzapine Monotherapy Studies </span></caption>
<col width="25%">
<col width="27%">
<col width="13%">
<col width="9%">
<col width="16%">
<col width="10%">
<col width="15%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="14" valign="top">
<span class="Sup">a</span> Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Up to 12 weeks exposure </span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">At least 24 weeks exposure </span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Laboratory Analyte </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Category Change (at least 	once) from Baseline </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Treatment Arm </span></p></td>
<td valign="top"><p class="First"><span class="Bold">N </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients </span></p></td>
<td valign="top"><p class="First"><span class="Bold">N </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients </span></p></td>
</tr>
<tr>
<td rowspan="4" valign="top"><p class="First"> 	Fasting Glucose </p></td>
<td rowspan="2" valign="top"><p class="First"> Normal to High 	(&lt;100 mg/dL to ≥126 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 124 </p></td>
<td valign="top"><p class="First"> 0% </p></td>
<td valign="top"><p class="First"> 108 </p></td>
<td valign="top"><p class="First"> 0.9% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 53 </p></td>
<td valign="top"><p class="First"> 1.9% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Borderline to High (≥100 mg/dL and &lt;126 mg/dL to 	≥126 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 14 </p></td>
<td valign="top"><p class="First"> 14.3% </p></td>
<td valign="top"><p class="First"> 13 </p></td>
<td valign="top"><p class="First"> 23.1% </p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Placebo </p></td>
<td class="Botrule" valign="top"><p class="First"> 13 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0% </p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8bcdf333-e6c5-41cc-9c8a-bc83f4a66973"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </h2>
<p class="First">Undesirable alterations in lipids have been observed with olanzapine and fluoxetine HCl use. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using olanzapine and fluoxetine HCl, is recommended <span class="Italics">[see Patient Counseling Information (<a href="#inv-668476de-d4ae-413c-8479-ee349dc2491c">17.6</a>)]</span>.</p>
<p>Clinically meaningful, and sometimes very high (&gt;500 mg/dL), elevations in triglyceride levels have been observed with olanzapine and fluoxetine HCl use. Clinically meaningful increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> have also been seen with olanzapine and fluoxetine HCl use.</p>
<p>In an analysis of 7 controlled clinical studies, 2 of which were placebo-controlled, with treatment duration up to 12 weeks, olanzapine and fluoxetine HCl -treated patients had an increase from baseline in mean random total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 12.1 mg/dL compared to an increase from baseline in mean random total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 4.8 mg/dL for olanzapine-treated patients and a decrease in mean random total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 5.5 mg/dL for placebo-treated patients. <span class="Bold">Table 4</span> shows categorical changes in nonfasting lipid values. </p>
<p>In long-term olanzapine and fluoxetine in combination studies (at least 48 weeks), changes (at least once) in nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from normal at baseline to high occurred in 12% (N=150) and changes from borderline to high occurred in 56.6% (N=143) of patients. The mean change in nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 11.3 mg/dL (N= 426).</p>
<a name="_Refinv-b0122dd4-0801-4509-8ecc-6b8e82b4"></a><table>
<caption><span>Table 4: Changes in Nonfasting Lipids Values from Controlled Clinical Studies with Treatment Duration up to 12 Weeks</span></caption>
<col width="37%">
<col width="48%">
<col width="14%">
<col width="6%">
<col width="10%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Laboratory Analyte </span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">Category Change (at least 	once) from Baseline </span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">Treatment Arm </span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">N </span></p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Patients </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="6" valign="top"><p class="First"> Nonfasting Triglycerides </p></td>
<td class="Botrule" rowspan="2" valign="top"><p class="First"> Increase by 	≥50 mg/dL </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 174 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 67.8% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 172 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 72.7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2" valign="top"><p class="First"> Normal to 	High (&lt;150 mg/dL to ≥500 mg/dL) </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 57 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 0% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 58 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 0% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2" valign="top"><p class="First"> Borderline to High (≥150 mg/dL and &lt;500 mg/dL to 	≥500 mg/dL) </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 106 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 15.1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 103 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 8.7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="9" valign="top"><p class="First"> Nonfasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> </p></td>
<td class="Botrule" rowspan="3" valign="top"><p class="First"> Increase by 	≥40 mg/dL </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 685 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 35% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 749 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 22.7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Placebo </p></td>
<td class="Botrule" valign="top"><p class="First"> 390 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 9% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"> Normal to 	High (&lt;200 mg/dL to ≥240 mg/dL) </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 256 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 8.2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 279 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 2.9% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Placebo </p></td>
<td class="Botrule" valign="top"><p class="First"> 175 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 1.7% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"> Borderline to High (≥200 mg/dL and &lt;240 mg/dL to 	≥240 mg/dL) </p></td>
<td class="Botrule" valign="top"><p class="First"> OFC </p></td>
<td class="Botrule" valign="top"><p class="First"> 213 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 36.2% </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine </p></td>
<td class="Botrule" valign="top"><p class="First"> 261 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 27.6% </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> Placebo </p></td>
<td class="Botrule" valign="top"><p class="First"> 111 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 9.9% </p></td>
</tr>
</tbody>
</table>
<p>Fasting lipid data is limited for olanzapine and fluoxetine HCl; however, in an analysis of 5 placebo-controlled olanzapine monotherapy studies with treatment duration up to 12 weeks, olanzapine-treated patients had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.3 mg/dL, 3.0 mg/dL, and 20.8 mg/dL respectively compared to decreases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 6.1 mg/dL, 4.3 mg/dL, and 10.7 mg/dL for placebo-treated patients. For fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, no clinically meaningful differences were observed between olanzapine-treated patients and placebo-treated patients. Mean increases in fasting lipid values (total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline, where lipid dysregulation was defined as patients diagnosed with <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> or related adverse reactions, patients treated with lipid lowering agents, patients with high baseline lipid levels.</p>
<p>In long-term olanzapine studies (at least 48 weeks), patients had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.6 mg/dL, 2.5 mg/dL, and 18.7 mg/dL, respectively, and a mean decrease in fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 0.16 mg/dL. In an analysis of patients who completed 12 months of therapy, the mean nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> did not increase further after approximately 4 to 6 months.</p>
<p>The proportion of olanzapine-treated patients who had changes (at least once) in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides from normal or borderline to high, or changes in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> from normal or borderline to low, was greater in long-term studies (at least 48 weeks) as compared with short-term studies. <span class="Bold">Table 5</span> shows categorical changes in fasting lipids values. </p>
<a name="_Refinv-ba59e56b-5988-4f8a-8f1f-d482ae40"></a><table>
<caption><span>Table 5: Changes in Fasting Lipids Values from Adult Olanzapine Monotherapy Studies </span></caption>
<col width="22%">
<col width="26%">
<col width="13%">
<col width="10%">
<col width="17%">
<col width="10%">
<col width="16%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="12" valign="top">
<span class="Sup">a</span> Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Up to 12 weeks 	exposure</span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">At least 48 weeks 	exposure</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Laboratory Analyte </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Category Change (at least 	once) from Baseline </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Treatment Arm </span></p></td>
<td valign="top"><p class="First"><span class="Bold">N </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients </span></p></td>
<td valign="top"><p class="First"><span class="Bold">N </span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients </span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Increase by ≥50 mg/dL </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 745 </p></td>
<td valign="top"><p class="First"> 39.6% </p></td>
<td valign="top"><p class="First"> 487 </p></td>
<td valign="top"><p class="First"> 61.4% </p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 402 </p></td>
<td valign="top"><p class="First"> 26.1% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Fasting </p></td>
<td valign="top"><p class="First"> Normal to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 457 </p></td>
<td valign="top"><p class="First"> 9.2% </p></td>
<td valign="top"><p class="First"> 293 </p></td>
<td valign="top"><p class="First"> 32.4% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Triglycerides </p></td>
<td valign="top"><p class="First"> (&lt;150 mg/dL to ≥200 	mg/dL) </p></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 251 </p></td>
<td valign="top"><p class="First"> 4.4% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Borderline to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 135 </p></td>
<td valign="top"><p class="First"> 39.3% </p></td>
<td valign="top"><p class="First"> 75 </p></td>
<td valign="top"><p class="First"> 70.7% </p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> (≥150 mg/dL and &lt;200 	mg/dL to ≥200 mg/dL) </p></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 65 </p></td>
<td valign="top"><p class="First"> 20.0% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Increase by ≥40 mg/dL </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 745 </p></td>
<td valign="top"><p class="First"> 21.6% </p></td>
<td valign="top"><p class="First"> 489 </p></td>
<td valign="top"><p class="First"> 32.9% </p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 402 </p></td>
<td valign="top"><p class="First"> 9.5% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Fasting </p></td>
<td valign="top"><p class="First"> Normal to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 392 </p></td>
<td valign="top"><p class="First"> 2.8% </p></td>
<td valign="top"><p class="First"> 283 </p></td>
<td valign="top"><p class="First"> 14.8% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> </p></td>
<td valign="top"><p class="First"> (&lt;200 mg/dL to ≥240 	mg/dL) </p></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 207 </p></td>
<td valign="top"><p class="First"> 2.4% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Borderline to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 222 </p></td>
<td valign="top"><p class="First"> 23.0% </p></td>
<td valign="top"><p class="First"> 125 </p></td>
<td valign="top"><p class="First"> 55.2% </p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> (≥200 mg/dL and &lt;240 	mg/dL to ≥240 mg/dL) </p></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 112 </p></td>
<td valign="top"><p class="First"> 12.5% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Increase by ≥30 mg/dL </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 536 </p></td>
<td valign="top"><p class="First"> 23.7% </p></td>
<td valign="top"><p class="First"> 483 </p></td>
<td valign="top"><p class="First"> 39.8% </p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 304 </p></td>
<td valign="top"><p class="First"> 14.1% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Fasting </p></td>
<td valign="top"><p class="First"> Normal to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 154 </p></td>
<td valign="top"><p class="First"> 0% </p></td>
<td valign="top"><p class="First"> 123 </p></td>
<td valign="top"><p class="First"> 7.3% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> </p></td>
<td valign="top"><p class="First"> (&lt;100 mg/dL to ≥160 	mg/dL) </p></td>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 82 </p></td>
<td valign="top"><p class="First"> 1.2% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
<tr>
<td valign="top"></td>
<td valign="top"><p class="First"> Borderline to High </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 302 </p></td>
<td valign="top"><p class="First"> 10.6% </p></td>
<td valign="top"><p class="First"> 284 </p></td>
<td valign="top"><p class="First"> 31.0% </p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" valign="top"><p class="First"> (≥100 mg/dL and &lt;160 	mg/dL to ≥160 mg/dL)</p></td>
<td class="Botrule" valign="top"><p class="First"> Placebo</p></td>
<td class="Botrule" valign="top"><p class="First"> 173</p></td>
<td class="Botrule" valign="top"><p class="First"> 8.1%</p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a</span></p></td>
</tr>
</tbody>
</table>
<p>In phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), over a median exposure of 9.2 months, the mean increase in triglycerides in patients taking olanzapine was 40.5 mg/dL. In phase 1 of CATIE, the median increase in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> was 9.4 mg/dL.</p>
<p><span class="Underline">Olanzapine Monotherapy in Adolescents </span>— The safety and efficacy of olanzapine and fluoxetine in combination have not been established in patients under the age of 18 years. The safety and efficacy of olanzapine have not been established in patients under the age of 13 years.</p>
<p>In an analysis of 3 placebo-controlled olanzapine monotherapy studies of adolescents, including those with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (6 weeks) or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes) (3 weeks), olanzapine-treated adolescents had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 12.9 mg/dL, 6.5 mg/dL, and 28.4 mg/dL, respectively, compared to increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 1.3 mg/dL and 1.0 mg/dL, and a decrease in triglycerides of 1.1 mg/dL for placebo-treated adolescents. For fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, no clinically meaningful differences were observed between olanzapine-treated adolescents and placebo-treated adolescents.</p>
<p>In long-term olanzapine studies (at least 24 weeks), adolescents had increases from baseline in mean fasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides of 5.5 mg/dL, 5.4 mg/dL, and 20.5 mg/dL, respectively, and a mean decrease in fasting HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 4.5 mg/dL. <span class="Bold">Table 6</span> shows categorical changes in fasting lipids values in adolescents. </p>
<a name="_Refinv-427e96c0-33a2-4e76-bdfc-633f6eee"></a><table>
<caption><span>Table 6: Changes in Fasting Lipids Values from Adolescent Olanzapine Monotherapy Studies </span></caption>
<col width="25%">
<col width="26%">
<col width="13%">
<col width="9%">
<col width="16%">
<col width="10%">
<col width="16%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="19" valign="top">
<span class="Sup">a</span> Not Applicable</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Up to 6 weeks 	exposure</span></p></td>
<td class="Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">At least 24 weeks 	exposure</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Laboratory 	Analyte</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Category Change (at least 	once) from Baseline</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Treatment Arm</span></p></td>
<td valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients</span></p></td>
<td valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td valign="top"><p class="First"><span class="Bold">Patients</span></p></td>
</tr>
<tr>
<td rowspan="8" valign="top"><p class="First"> 	Fasting Triglycerides </p></td>
<td rowspan="2" valign="top"><p class="First"> Increase by 	≥50 mg/dL </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 138 </p></td>
<td valign="top"><p class="First"> 37.0% </p></td>
<td valign="top"><p class="First"> 122 </p></td>
<td valign="top"><p class="First"> 45.9% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 66 </p></td>
<td valign="top"><p class="First"> 15.2% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Normal to 	High (&lt;90 mg/dL to &gt;130 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 67 </p></td>
<td valign="top"><p class="First"> 26.9% </p></td>
<td valign="top"><p class="First"> 66 </p></td>
<td valign="top"><p class="First"> 36.4% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 28 </p></td>
<td valign="top"><p class="First"> 10.7% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Borderline to High (≥90 mg/dL and ≤130 mg/dL to 	&gt;130 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 37 </p></td>
<td valign="top"><p class="First"> 59.5% </p></td>
<td valign="top"><p class="First"> 31 </p></td>
<td valign="top"><p class="First"> 64.5% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 17 </p></td>
<td valign="top"><p class="First"> 35.3% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Increase 	by ≥40 mg/dL </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 138 </p></td>
<td valign="top"><p class="First"> 14.5% </p></td>
<td valign="top"><p class="First"> 122 </p></td>
<td valign="top"><p class="First"> 14.8% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 66 </p></td>
<td valign="top"><p class="First"> 4.5% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="4" valign="top"><p class="First"> 	Fasting Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>  </p></td>
<td rowspan="2" valign="top"><p class="First"> Normal to High 	(&lt;170 mg/dL to ≥200 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 87 </p></td>
<td valign="top"><p class="First"> 6.9% </p></td>
<td valign="top"><p class="First"> 78 </p></td>
<td valign="top"><p class="First"> 7.7% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 43 </p></td>
<td valign="top"><p class="First"> 2.3% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Borderline to High (≥170 mg/dL and &lt;200 mg/dL to 	≥200 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 36 </p></td>
<td valign="top"><p class="First"> 38.9% </p></td>
<td valign="top"><p class="First"> 33 </p></td>
<td valign="top"><p class="First"> 57.6% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo</p></td>
<td valign="top"><p class="First"> 13 </p></td>
<td valign="top"><p class="First"> 7.7% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="6" valign="top"><p class="First"> 	Fasting LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> </p></td>
<td rowspan="2" valign="top"><p class="First"> Increase by 	≥30 mg/dL</p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 137 </p></td>
<td valign="top"><p class="First"> 17.5% </p></td>
<td valign="top"><p class="First"> 121 </p></td>
<td valign="top"><p class="First"> 22.3% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 63 </p></td>
<td valign="top"><p class="First"> 11.1% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Normal to 	High (&lt;110 mg/dL to ≥130 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine  </p></td>
<td valign="top"><p class="First"> 98 </p></td>
<td valign="top"><p class="First"> 5.1% </p></td>
<td valign="top"><p class="First"> 92 </p></td>
<td valign="top"><p class="First"> 10.9% </p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Placebo </p></td>
<td valign="top"><p class="First"> 44 </p></td>
<td valign="top"><p class="First"> 4.5% </p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
<tr>
<td rowspan="2" valign="top"><p class="First"> Borderline to High (≥110 mg/dL and &lt;130 mg/dL to 	≥130 mg/dL) </p></td>
<td valign="top"><p class="First"> Olanzapine </p></td>
<td valign="top"><p class="First"> 29 </p></td>
<td valign="top"><p class="First"> 48.3% </p></td>
<td valign="top"><p class="First"> 21 </p></td>
<td valign="top"><p class="First"> 47.6% </p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Placebo </p></td>
<td class="Botrule" valign="top"><p class="First"> 9 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0% </p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
<td class="Botrule" valign="top"><p class="First"> NA<span class="Sup">a </span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c82e5c02-0ff3-4459-bf36-bcc21c54d8a4"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> </h2>
<p class="First">Potential consequences of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be considered prior to starting olanzapine and fluoxetine HCl. Patients receiving olanzapine and fluoxetine HCl should receive regular monitoring of weight <span class="Italics">[see Patient Counseling Information (<a href="#inv-8b6ac083-965e-4d3e-aee0-badc8a92a67c">17.7</a>)]</span>.</p>
<p>In an analysis of 7 controlled clinical studies, 2 of which were placebo-controlled, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span> for olanzapine and fluoxetine HCl -treated patients was greater than placebo-treated patients [4 kg (8.8 lb) vs -0.3 kg (-0.7 lb)]. Twenty-two percent of olanzapine and fluoxetine HCl-treated patients gained at least 7% of their baseline weight, with a median exposure to event of 6 weeks. This was greater than in placebo-treated patients (1.8%). Approximately 3% of olanzapine and fluoxetine HCl -treated patients gained at least 15% of their baseline weight, with a median exposure to event of 8 weeks. This was greater than in placebo-treated patients (0%). Clinically significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was observed across all baseline Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) categories. Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 2.5% of olanzapine and fluoxetine HCl -treated patients and 0% of placebo-treated patients.</p>
<p>In long-term olanzapine and fluoxetine in combination studies (at least 48 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 6.7 kg (14.7 lb) (median exposure of 448 days, N=431). The percentages of patients who gained at least 7%, 15% or 25% of their baseline body weight with long-term exposure were 66%, 33%, and 10%, respectively. Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 1.2% of patients treated with olanzapine and fluoxetine in combination following at least 48 weeks of exposure.</p>
<p>In long-term olanzapine studies (at least 48 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 5.6 kg (12.3 lb) (median exposure of 573 days, N=2021). The percentages of patients who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 64%, 32%, and 12%, respectively. Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 0.4% of olanzapine-treated patients following at least 48 weeks of exposure.</p>
<p><span class="Bold">Table 7</span> includes data on adult <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> with olanzapine pooled from 86 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified. </p>
<a name="_Refinv-2c9fa205-11ee-4f65-a38e-37ac4c43"></a><table>
<caption><span>Table 7: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in Adults</span></caption>
<col width="15%">
<col width="16%">
<col width="22%">
<col width="22%">
<col width="21%">
<col width="21%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Amount Gained </span> 	kg (lb)</p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">6 Weeks</span> (N=7465) 	(%)</p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">6 Months                            	(N=4162) (%)</span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">12 Months                            	(N=1345) (%)</span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">24 Months                             	(N=474) (%) </span></p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">36 Months                            	(N=147) (%) </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> ≤0</p></td>
<td class="Botrule" valign="top"><p class="First"> 26.2 </p></td>
<td class="Botrule" valign="top"><p class="First"> 24.3 </p></td>
<td class="Botrule" valign="top"><p class="First"> 20.8 </p></td>
<td class="Botrule" valign="top"><p class="First"> 23.2 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 17.0 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> 0 to ≤5 (0-11 	lb)</p></td>
<td class="Botrule" valign="top"><p class="First"> 57.0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 36.0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 26.0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 23.4 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 25.2 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;5 to ≤10 (11-22 	lb)</p></td>
<td class="Botrule" valign="top"><p class="First"> 14.9 </p></td>
<td class="Botrule" valign="top"><p class="First"> 24.6 </p></td>
<td class="Botrule" valign="top"><p class="First"> 24.2 </p></td>
<td class="Botrule" valign="top"><p class="First"> 24.1 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 18.4 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;10 to ≤15 (22-33 	lb)</p></td>
<td class="Botrule" valign="top"><p class="First"> 1.8 </p></td>
<td class="Botrule" valign="top"><p class="First"> 10.9 </p></td>
<td class="Botrule" valign="top"><p class="First"> 14.9 </p></td>
<td class="Botrule" valign="top"><p class="First"> 11.4 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 17.0 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;15 to ≤20 (33-44 	lb) </p></td>
<td class="Botrule" valign="top"><p class="First"> 0.1 </p></td>
<td class="Botrule" valign="top"><p class="First"> 3.1 </p></td>
<td class="Botrule" valign="top"><p class="First"> 8.6 </p></td>
<td class="Botrule" valign="top"><p class="First"> 9.3 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 11.6 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;20 to ≤25 (44-55 	lb) </p></td>
<td class="Botrule" valign="top"><p class="First"> 0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0.9 </p></td>
<td class="Botrule" valign="top"><p class="First"> 3.3 </p></td>
<td class="Botrule" valign="top"><p class="First"> 5.1 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 4.1 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;25 to ≤30 (55-66 	lb) </p></td>
<td class="Botrule" valign="top"><p class="First"> 0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0.2 </p></td>
<td class="Botrule" valign="top"><p class="First"> 1.4 </p></td>
<td class="Botrule" valign="top"><p class="First"> 2.3 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 4.8 </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> &gt;30 (&gt;66 lb) </p></td>
<td class="Botrule" valign="top"><p class="First"> 0 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0.1 </p></td>
<td class="Botrule" valign="top"><p class="First"> 0.8 </p></td>
<td class="Botrule" valign="top"><p class="First"> 1.2 </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 2 </p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Olanzapine Monotherapy in Adolescents </span>— The safety and efficacy of olanzapine and fluoxetine in combination have not been established in patients under the age of 18 years. The safety and efficacy of olanzapine have not been established in patients under the age of 13 years. Mean increase in weight in adolescents was greater than in adults. In 4 placebo-controlled trials, discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 1% of olanzapine-treated patients, compared to 0% of placebo-treated patients. </p>
<a name="_Refinv-9d987d51-285a-46ec-a775-c776ca19"></a><table>
<caption><span>Table 8: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in Adolescents from 4 Placebo-Controlled Trials </span></caption>
<col width="49%">
<col width="34%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">Olanzapine-treated 	patients</span></p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Placebo-treated 	patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Mean change in body 	weight from baseline (median exposure = 3 	weeks)</p></td>
<td class="Botrule" valign="top"><p class="First"> 4.6 kg (10.1 lb)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 0.3 kg (0.7 lb)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Percentage of 	patients who gained at least 7% of baseline body 	weight</p></td>
<td class="Botrule" valign="top"><p class="First"> 40.6% (median exposure to 	7% = 4 weeks)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 9.8% (median exposure to 	7% = 8 weeks) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> Percentage of 	patients who gained at least 15% of baseline body 	weight</p></td>
<td class="Botrule" valign="top"><p class="First"> 7.1% (median exposure to 	15% = 19 weeks)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 2.7% (median exposure to 	15% = 8 weeks)</p></td>
</tr>
</tbody>
</table>
<p>In long-term olanzapine studies (at least 24 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 11.2 kg (24.6 lb) (median exposure of 201 days, N=179). The percentages of adolescents who gained at least 7%, 15%, or 25% of their baseline body weight with long-term exposure were 89%, 55%, and 29%, respectively. Among adolescent patients, mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> by baseline BMI category was 11.5 kg (25.3 lb), 12.1 kg (26.6 lb), and 12.7 kg (27.9 lb), respectively, for normal (N=106), overweight (N=26) and obese (N=17). Discontinuation due to <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurred in 2.2% of olanzapine-treated patients following at least 24 weeks of exposure.</p>
<p><span class="Bold">Table 9</span> shows data on adolescent <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> with olanzapine pooled from 6 clinical trials. The data in each column represent data for those patients who completed treatment periods of the durations specified. Little clinical trial data is available on <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in adolescents with olanzapine beyond 6 months of treatment. </p>
<a name="_Refinv-df849ed9-069b-4d16-af6c-306e3960"></a><table>
<caption><span>Table 9: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> with Olanzapine Use in Adolescents</span></caption>
<col width="25%">
<col width="22%">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Amount GainedKg (lb)</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">6 Weeks(N=243)(%)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">6 Months(N=191)(%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Underline">≤0</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2.9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> 0 to ≤5(0 to 11 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 47.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 24.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;5 to ≤10 (11 to 22 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 42.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 26.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;10 to ≤15 (22 to 33 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 5.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 22.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;15 to ≤20 (33 to 44 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 12.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;20 to ≤25 (44 to 55 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 9.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;25 to ≤30 (55 to 66 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;30 to ≤35 (66 to 77 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;35 to ≤40 (77 to 88 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> &gt;40 (&gt;88 lb)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0.5</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> has been reported with SNRIs and SSRIs including olanzapine and fluoxetine, alone but particularly with concomitant use of serotonergic drugs (including triptans, tricyclic antidepressants ), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>
<p><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
<p>The concomitant use of olanzapine and fluoxetine with MAOIs intended to treat psychiatric disorders is contraindicated. Olanzapine and fluoxetine should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided informations on the route of administration involved intravenous administration in the dose range of 1mg/kg to 8mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking olanzapine and fluoxetine. Olanzapine and fluoxetine should be discontinued before initiating treatment with the MAOI [see <span class="Italics">Dosage and Adminstration (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>, and <a href="#ID_27db6d82-35cd-467d-b7c8-7c21ff488e83">2.5</a>) and Contraindications (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>)</span>].</p>
<p>If concomitant use of  olanzapine and fluoxetine with other serotonergic drugs including triptans, tricyclic anitdepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John’s Wort is clinically warranted, patients should be made aware of a potential increased risk for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly during treatment initation and dose increases.</p>
<p>Treatment with olanzapine and fluoxetine and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f9bf1ec3-d4d7-4c6a-b32e-8857b18039a6"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </h2>
<p class="First">In olanzapine and fluoxetine HCl premarketing controlled clinical studies, the overall incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in olanzapine and fluoxetine HCl -treated patients [4.6% (26/571)] was similar to that of placebo [5.2% (25/477)]. The majority of the cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> were mild; however, 3 patients discontinued (1 due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, which was moderate in severity and 2 due to <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, 1 of which included face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>).</p>
<p>In fluoxetine US clinical studies, 7% of 10,782 fluoxetine-treated patients developed various types of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Among the cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> reported in premarketing clinical studies, almost a third were withdrawn from treatment because of the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and/or systemic signs or symptoms associated with the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Clinical findings reported in association with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, and mild transaminase elevation. Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely.</p>
<p>In fluoxetine premarketing clinical studies, 2 patients are known to have developed a serious cutaneous systemic illness. In neither patient was there an unequivocal diagnosis, but 1 was considered to have a <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, and the other, a severe desquamating syndrome that was considered variously to be a <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> or <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>. Other patients have had systemic syndromes suggestive of <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>.</p>
<p>Since the introduction of fluoxetine, systemic reactions, possibly related to <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, have developed in patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Although these reactions are rare, they may be serious, involving the lung, kidney, or liver. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported to occur in association with these systemic reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> alone and in combination, have been reported.</p>
<p>Pulmonary reactions, including inflammatory processes of varying histopathology and/or <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, have been reported rarely. These reactions have occurred with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> as the only preceding symptom.</p>
<p>Whether these systemic reactions and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have a common underlying cause or are due to different etiologies or pathogenic processes is not known. Furthermore, a specific underlying immunologic basis for these reactions has not been identified. Upon the appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or of other possible allergic phenomena for which an alternative etiology cannot be identified, olanzapine and fluoxetine HCl should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9040c9ad-a5b3-4c8b-b186-9b95492ada13"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span> </h2>
<p class="First">A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of Bipolar Disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, Bipolar Disorder, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that olanzapine and fluoxetine HCl is approved for the acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>.</p>
<p>In the 2 controlled <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span> studies there was no statistically significant difference in the incidence of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">manic depressive reaction</span>) between olanzapine and fluoxetine HCl -and placebo-treated patients. In 1 of the studies, the incidence of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span> was (7% [3/43]) in olanzapine and fluoxetine HCl -treated patients compared to (3% [5/184]) in placebo-treated patients. In the other study, the incidence of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span> was (2% [1/43]) in olanzapine and fluoxetine HCl -treated patients compared to (8% [15/193]) in placebo-treated patients. This limited controlled trial experience of olanzapine and fluoxetine HCl in the acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> makes it difficult to interpret these findings until additional data is obtained. Because of this and the cyclical nature of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, patients should be monitored closely for the development of symptoms of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> during treatment with olanzapine and fluoxetine HCl.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-7ba4bd83-7da8-4d96-a82d-16f449dd9571"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> </h2>
<p class="First">A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.</p>
<p>The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>The incidence of dyskinetic movement in olanzapine and fluoxetine HCl -treated patients was infrequent. The mean score on the Abnormal Involuntary Movement Scale (AIMS) in the olanzapine and fluoxetine HCl -controlled database across clinical studies involving olanzapine and fluoxetine HCl -treated patients decreased from baseline. Nonetheless, olanzapine and fluoxetine HCl should be prescribed in a manner that is most likely to minimize the risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on olanzapine and fluoxetine HCl, drug discontinuation should be considered. However, some patients may require treatment with olanzapine and fluoxetine HCl despite the presence of the syndrome. The need for continued treatment should be reassessed periodically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-66597682-6f74-44e5-9c0e-69b9d506a574"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </h2>
<p class="First">Olanzapine and fluoxetine HCl may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and, in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the initial dose-titration period <span class="Italics">[see Patient Counseling Information (<a href="#inv-02172586-1d30-4027-9852-ee60361b0dd9">17.10</a>)]</span>. </p>
<p>In the olanzapine and fluoxetine HCl -controlled clinical trials across all indications, there were no significant differences between olanzapine and fluoxetine HCl -treated patients and olanzapine, fluoxetine-or placebo-treated patients in exposure-adjusted rates of orthostatic systolic blood pressure decreases of at least 30 mm Hg. Orthostatic systolic blood pressure decreases of at least 30 mm Hg occurred in 4.0% (28/705), 2.3% (19/831), 4.5% (18/399), and 1.8% (8/442) of the olanzapine and fluoxetine HCl, olanzapine, fluoxetine, and placebo groups, respectively. In this group of studies, the incidence of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>-related adverse reactions (i.e., <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and/or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>) in olanzapine and fluoxetine HCl -treated patients was 0.4% (3/771) compared to placebo 0.2% (1/477).</p>
<p>In a clinical pharmacology study of olanzapine and fluoxetine HCl, 3 healthy subjects were discontinued from the trial after experiencing severe, but self-limited, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> that occurred 2 to 9 hours following a single 12 mg/50 mg dose of olanzapine and fluoxetine HCl. Reactions consisting of this combination of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> (and also accompanied by sinus pause) have been observed in at least 3 other healthy subjects treated with various formulations of olanzapine (1 oral, 2 intramuscular). In controlled clinical studies, the incidence of patients with a ≥20 bpm decrease in orthostatic pulse concomitantly with a ≥20 mm Hg decrease in orthostatic systolic blood pressure was 0.3% (2/706) in the olanzapine and fluoxetine HCl group, 0.2% (1/445) in the placebo group, 0.7% (6/837) in the olanzapine group, and 0% (0/404) in the fluoxetine group.</p>
<p>Olanzapine and fluoxetine HCl should be used with particular caution in patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (<span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-b11644fe-433b-45a8-a30d-4f1fbc2a85bb"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> </h2>
<p class="First"><span class="Underline">Class Effect </span>-In clinical trial and/or postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including olanzapine and fluoxetine HCl. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> has also been reported. </p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include preexisting low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a history of a clinically significant low WBC or drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of olanzapine and fluoxetine HCl should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>
<p>Patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm <span class="Sup">3</span>) should discontinue olanzapine and fluoxetine HCl and have their WBC followed until recovery. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-c025194d-c59a-401e-8efe-b985f2e533bd"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in patients with advanced Alzheimer's disease. Olanzapine and fluoxetine HCl is not approved for the treatment of patients with Alzheimer's disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-cb14208f-4d7d-49ed-b151-fb0894fb510c"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> occurred in 0.2% (4/2547) of olanzapine and fluoxetine HCl -treated patients during open-label clinical studies. No <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in the controlled olanzapine and fluoxetine HCl studies. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have also been reported with both olanzapine and fluoxetine monotherapy. Olanzapine and fluoxetine HCl should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that potentially lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Olanzapine and fluoxetine HCl is not approved for the treatment of patients with Alzheimer's disease. Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in a population of ≥65 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-09cc51c9-342e-45cb-9784-0429d5c0b351"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </h2>
<p class="First">SNRIs and SSRIs, including fluoxetine, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> reactions. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> reactions related to SNRIs and SSRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>.</p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of olanzapine and fluoxetine HCl and NSAIDs, aspirin, or other drugs that affect coagulation <span class="Italics">[see Drug Interactions (<a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6</a>) and Patient Counseling Information (<a href="#inv-747ea154-3045-4e08-bebd-fe2649705581">17.11</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9e6d3f5a-bb88-4467-af87-c86e9acdf898"></a><a name="section-5.16"></a><p></p>
<h2>5.16 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> has been reported during treatment with SNRIs and SSRIs, including fluoxetine and olanzapine and fluoxetine HCl. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when olanzapine and fluoxetine HCl was discontinued. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SNRIs and SSRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk <span class="Italics">[see Use in Specific Populations (<a href="#inv-592f745a-0a5f-4fc0-aac0-084a49716dae">8.5</a>)]</span>. Discontinuation of olanzapine and fluoxetine HCl should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted. </p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Italics">[See Patient Counseling Information (<a href="#inv-de88a31f-4d03-4e4e-a0de-1ecc86fe8439">17.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-3dee430c-291b-4312-8599-821fed557a6c"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Potential for Cognitive and Motor Impairment </h2>
<p class="First">Sedation-related adverse reactions were commonly reported with olanzapine and fluoxetine HCl treatment occurring at an incidence of 26.6% in olanzapine and fluoxetine HCl -treated patients compared with 10.9% in placebo-treated patients. Sedation-related adverse reactions (sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>) led to discontinuation in 2% (15/771) of patients in the controlled clinical studies. As with any CNS-active drug, olanzapine and fluoxetine HCl has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that olanzapine and fluoxetine HCl therapy does not affect them adversely <span class="Italics">[see Patient Counseling Information (<a href="#inv-73cc8ada-adee-4aac-b328-b8955309fab0">17.13</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9fecc0ec-b6a9-411f-8be5-1dc51cf674db"></a><a name="section-5.18"></a><p></p>
<h2>5.18 Body Temperature Regulation </h2>
<p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic drugs. Appropriate care is advised when prescribing olanzapine and fluoxetine HCl for patients who will be experiencing conditions which may contribute to an elevation in core body temperature (e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>). <span class="Italics">[See Patient Counseling Information (<a href="#inv-73cc8ada-adee-4aac-b328-b8955309fab0">17.13</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-dcf51e09-887d-44e2-aefc-a33f024fceb4"></a><a name="section-5.19"></a><p></p>
<h2>5.19 Use in Patients with Concomitant Illness </h2>
<p class="First">Clinical experience with olanzapine and fluoxetine HCl in patients with concomitant systemic illnesses is limited <span class="Italics">[see Clinical Pharmacology (<a href="#inv-8423052d-ce2b-47a2-9ef2-b47e30cb1fc4">12.4</a>)]</span>. The following precautions for the individual components may be applicable to olanzapine and fluoxetine HCl. </p>
<p>Olanzapine exhibits <span class="Italics">in vitro</span> muscarinic receptor affinity. In premarketing clinical studies, olanzapine and fluoxetine HCl was associated with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, all adverse reactions possibly related to cholinergic antagonism. Such adverse reactions were not often the basis for study discontinuations; olanzapine and fluoxetine HCl should be used with caution in patients with clinically significant <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, a history of <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>, or related conditions. </p>
<p>In 5 placebo-controlled studies of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (n=1184), the following treatment-emergent adverse reactions were reported in olanzapine-treated patients at an incidence of at least 2% and significantly greater than placebo-treated patients: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, increased weight, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>. The rate of discontinuation due to adverse reactions was significantly greater with olanzapine than placebo (13% vs 7%). Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with olanzapine are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Boxed Warning, Warnings and Precautions (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>), and Patient Counseling Information (<a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>)]</span>. </p>
<p>As with other CNS-active drugs, olanzapine and fluoxetine HCl should be used with caution in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. If the prescriber elects to treat elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, vigilance should be exercised <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>), and Patient Counseling Information (<a href="#inv-7dcfd413-3789-430c-978f-8a123fc0ea13">17.3</a>)]</span>. </p>
<p>Olanzapine and fluoxetine HCl has not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease. Patients with these diagnoses were excluded from clinical studies during the premarket testing.</p>
<p>Caution is advised when using olanzapine and fluoxetine HCl in cardiac patients and in patients with diseases or conditions that could affect hemodynamic responses <span class="Italics">[see Warnings and Precautions (<a href="#inv-66597682-6f74-44e5-9c0e-69b9d506a574">5.11</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-4a8ae178-fcff-4c9f-b980-1c8db7209182"></a><a name="section-5.20"></a><p></p>
<h2>5.20 <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> </h2>
<p class="First">As with other drugs that antagonize dopamine D <span class="Sub">2</span> receptors, olanzapine and fluoxetine HCl elevates prolactin levels, and the elevation persists during administration. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> have been reported in patients receiving prolactin-elevating compounds. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male subjects. </p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. As is common with compounds that increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats <span class="Italics">[see Nonclinical Toxicology (<a href="#inv-5f98797a-89d1-49d2-b8c6-a25b5dfbf11d">13.1</a>)]</span>. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. </p>
<p>In controlled clinical studies of olanzapine and fluoxetine HCl (up to 12 weeks), changes from normal to high in prolactin concentrations were observed in 28% of adults treated with olanzapine and fluoxetine HCl as compared to 5% of placebo-treated patients. The elevations persisted throughout administration of olanzapine and fluoxetine HCl. In a pooled analysis from clinical studies including 2929 adults treated with olanzapine and fluoxetine HCl, potentially associated clinical manifestations included menstrual-related events <span class="Sup">1 </span>(1% [20/1946] of females), sexual function-related events<span class="Sup">2 </span>(7% [192/2929] of females and males), and breast-related events<span class="Sup">3 </span>(0.8% [16/1946] of females, 0.2% [2/983] of males). </p>
<p>In placebo-controlled olanzapine clinical studies (up to 12 weeks), changes from normal to high in prolactin concentrations were observed in 30% of adults treated with olanzapine as compared to 10.5% of adults treated with placebo. In a pooled analysis from clinical studies including 8136 adults treated with olanzapine, potentially associated clinical manifestations included menstrual-related events <span class="Sup">1 </span>(2% [49/3240] of females), sexual function-related events<span class="Sup">2 </span>(2% [150/8136] of females and males), and breast-related events<span class="Sup">3</span> (0.7% [23/3240] of females, 0.2% [9/4896] of males). </p>
<p>In placebo-controlled olanzapine monotherapy studies in adolescent patients (up to 6 weeks) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span> (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes), changes from normal to high in prolactin concentrations were observed in 47% of olanzapine-treated patients compared to 7% of placebo-treated patients. In a pooled analysis from clinical trials including 454 adolescents treated with olanzapine, potentially associated clinical manifestations included menstrual-related events <span class="Sup">1 </span>(1% [2/168] of females), sexual function-related events<span class="Sup">2 </span>(0.7% [3/454] of females and males), and breast-related events<span class="Sup">3 </span>(2% [3/168] of females, 2% [7/286] of males), <span class="Italics">[se</span>e <span class="Italics">Use in Specific Populations (<a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>)]</span>.</p>
<p><span class="Sup">1.</span>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4275882" conceptname="Hypomenorrhea">hypomenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4224178" conceptname="Menstrual period late">menstruation delayed</span>, and <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>.</p>
<p><span class="Sup">2.</span>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, delayed ejaculation, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, abnormal orgasm, and <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>.</p>
<p><span class="Sup">3.</span>Based on a search of the following terms: <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">breast discharge</span>, enlargement or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="80471" conceptname="Disorder of lactation">lactation disorder</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8154c760-2029-477b-9842-13b1b0f2a067"></a><a name="section-5.21"></a><p></p>
<h2>5.21 Concomitant Use of Olanzapine and Fluoxetine Products </h2>
<p class="First">Olanzapine and fluoxetine HCl contains the same active ingredients that are in Zyprexa <span class="Sup">®</span>, ZyprexaZydis<span class="Sup">® </span>(olanzapine), and in Prozac<span class="Sup">®</span>, ProzacWeekly<span class="Sup">™</span>, and Sarafem<span class="Sup">® </span>(fluoxetine HCl). Caution should be exercised when prescribing these medications concomitantly with olanzapine and fluoxetine HCl <span class="Italics">[see Overdosage (<a href="#inv-e69aceed-b284-4d29-aa7f-dea3f02cde38">10</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a681d8d5-0a95-4278-83e4-886f354eacaa"></a><a name="section-5.22"></a><p></p>
<h2>5.22 Long Elimination Half-Life of Fluoxetine </h2>
<p class="First">Because of the long elimination half-lives of fluoxetine and its major active metabolite, changes in dose will not be fully reflected in plasma for several weeks, affecting both strategies for titration to final dose and withdrawal from treatment. This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-9b672363-cf47-4954-99e9-869122a892c8"></a><a name="section-5.23"></a><p></p>
<h2>5.23 Discontinuation of Treatment with Olanzapine and Fluoxetine HCl </h2>
<p class="First">During marketing of fluoxetine, a component of olanzapine and fluoxetine HCl, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with fluoxetine. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and norfluoxetine concentration decrease gradually at the conclusion of therapy, which may minimize the risk of discontinuation symptoms with this drug <span class="Italics">[see Dosage and Administration (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>) and Patient Counseling Information (<a href="#inv-38d728dd-23cc-44ee-a024-b2c50938a75c">17.16</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-06ba434d-cd7e-44fe-a79a-11ed0e11ee05"></a><a name="section-5.24"></a><p></p>
<h2>5.24 Laboratory Tests </h2>
<p class="First">Fasting blood glucose testing and lipid profile at the beginning of, and periodically during, treatment is recommended <span class="Italics">[see Warnings and Precautions (<a href="#inv-d8179809-2795-4eff-a8f1-796f6db0940a">5.4</a>, <a href="#inv-8bcdf333-e6c5-41cc-9c8a-bc83f4a66973">5.5</a>) and Patient Counseling Information (<a href="#inv-5259af63-e319-46a8-9cc1-5f1125bd2e1f">17.5</a>, <a href="#inv-668476de-d4ae-413c-8479-ee349dc2491c">17.6</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="inv-705c1e23-75a5-4490-92ba-04a94097bf32"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS </h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f47d55bf-1a46-4360-b21f-f81aaea026cb"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">The information below is derived from a clinical study database for olanzapine and fluoxetine HCl consisting of 2547 patients with approximately 1085 patient-years of exposure. The conditions and duration of treatment with olanzapine and fluoxetine HCl varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or long-term exposure.</p>
<p>Adverse reactions were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a limited (i.e., reduced) number of standardized reaction categories.</p>
<p>In the tables and tabulations that follow, MedDRA or COSTART Dictionary terminology has been used to classify reported adverse reactions. The data in the tables represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is possible that reactions reported during therapy were not necessarily related to drug exposure.</p>
<p>The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing clinician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.</p>
<p><span class="Underline">Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Controlled Studies</span><span class="Underline"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with Bipolar 1 Disorder</span>— Overall, 11.3% of the 771 patients in the olanzapine and fluoxetine HCl group discontinued due to adverse reactions compared with 4.4% of the 477 patients for placebo. Adverse reactions leading to discontinuation associated with the use of olanzapine and fluoxetine HCl (incidence of at least 1% for olanzapine and fluoxetine HCl and greater than that for placebo) using MedDRA Dictionary coding were <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> (2%) and sedation (1%) versus placebo patients which had 0% incidence of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span> and sedation. </p>
<p><span class="Underline">Commonly Observed Adverse Reactions in Short-Term, Controlled Studies <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with Bipolar 1 Disorder</span>— The most commonly observed adverse reactions associated with the use of olanzapine and fluoxetine HCl (incidence ≥5% and at least twice that for placebo in the olanzapine and fluoxetine HCl -controlled database) using MedDRA Dictionary coding were: <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>. Adverse reactions reported in clinical trials of olanzapine and fluoxetine in combination are generally consistent with treatment-emergent adverse reactions during olanzapine or fluoxetine monotherapy. </p>
<p><span class="Underline">Adverse Reactions Occurring at an Incidence of 2% or More in Short-Term Controlled Studies <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with Bipolar 1 Disorder</span>— <span class="Bold">Table 10</span> enumerates the treatment-emergent adverse reactions associated with the use of olanzapine and fluoxetine HCl (incidence of at least 2% for olanzapine and fluoxetine HCl and twice or more than for placebo). The olanzapine and fluoxetine HCl -controlled column includes patients with various diagnoses while the placebo column includes only patients with <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span> and <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features. </p>
<a name="_Refinv-876b9432-b07f-485a-9a08-9b57563a"></a><table>
<caption><span>Table 10: Treatment-Emergent Adverse Reactions: Incidence in Controlled Clinical Studies </span></caption>
<col width="34%">
<col width="30%">
<col width="28%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">System Organ 	Class</span></p></td>
<td class="Botrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Percentage of Patients 	Reporting Event</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Olanzapine and Fluoxetine 	HCl-Controlled</span> (N=771)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span>   	(N-477)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 15</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Abdominal 	distension</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="6" valign="top"><p class="First"> General 	disorders and administration site conditions</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and 	<span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Investigations</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 25</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Metabolism and 	nutrition disorders</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 20</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"> Musculoskeletal and connective tissue 	disorders</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in 	extremity</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Musculoskeletal 	stiffnes</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="6" valign="top"><p class="First"> Nervous 	system disorders</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 9</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Sedation</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">Hypersomnia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Distrubance in 	attention</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"> Psychiatric disorders</p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Thinking 	abnormal</p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> Reproductive system 	and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></p></td>
<td class="Botrule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Erectile dysfunction</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"> 2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"> 1</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span> </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>, Class Effect for Antipsychotics </span>— Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, the frequency and severity are greater with high potency and at higher doses of first generation antipsychotic drugs. In general, an elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> may be observed in males and younger age groups receiving antipsychotics; however, events of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> have been reported infrequently (&lt;1%) with the olanzapine and fluoxetine combination. </p>
<p><span class="Underline">Additional Findings Observed in Clinical Studies </span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span> </span>— In the pool of controlled olanzapine and fluoxetine HCl studies in patients with <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>, there were higher rates of the treatment-emergent adverse reactions decreased libido, <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> and <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span> in the olanzapine and fluoxetine HCl group than in the placebo group. One case of decreased libido led to discontinuation in the olanzapine and fluoxetine HCl group. In the controlled studies that contained a fluoxetine arm, the rates of decreased libido and <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span> in the olanzapine and fluoxetine HCl group were less than the rates in the fluoxetine group. None of the differences were statistically significant.</p>
<p><span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual dysfunction</span>, including <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, has been reported with all SSRIs. While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.</p>
<p>There are no adequate and well-controlled studies examining dysfunction with olanzapine and fluoxetine HCl or fluoxetine treatment. Symptoms of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> occasionally persist after discontinuation of fluoxetine treatment.</p>
<p><span class="Underline">Difference Among Dose Levels Observed in Other Olanzapine Clinical Trials</span></p>
<p>In a single 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200), and 40 (N=200) mg/day of olanzapine in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">Schizoaffective Disorder</span>, statistically significant differences among 3 dose groups were observed for the following safety outcomes: <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, prolactin elevation, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. Mean baseline to endpoint increase in weight (10 mg/day: 1.9 kg; 20 mg/day: 2.3 kg; 40 mg/day: 3 kg) was observed with significant differences between 10 vs 40 mg/day. Incidence of treatment-emergent prolactin elevation &gt;24.2 ng/mL (female) or &gt;18.77 ng/mL (male) at any time during the trial (10 mg/day: 31.2%; 20 mg/day: 42.7%; 40 mg/day: 61.1%) with significant differences between 10 vs 40 mg/day and 20 vs 40 mg/day; <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (10 mg/day: 1.5%; 20 mg/day: 2.1%; 40 mg/day: 6.6%) with significant differences between 10 vs 40 and 20 vs 40 mg/day; and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (10 mg/day: 2.6%; 20 mg/day: 1.6%; 40 mg/day: 6.6%) with significant differences between 20 vs 40 mg, was observed.</p>
<p><span class="Underline">Other Adverse Reactions Observed in Clinical Studies </span></p>
<p>Following is a list of treatment-emergent adverse reactions reported by patients treated with olanzapine and fluoxetine HCl in clinical trials. This listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo.</p>
<p>Reactions are classified by body system using the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; and rare reactions are those occurring in fewer than 1/1000 patients.</p>
<p><span class="Bold">Body as a Whole </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">neck rigidity</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">1</span>. </p>
<p><span class="Bold">Cardiovascular System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="Italics">Infrequent: </span>QT-interval prolonged. </p>
<p><span class="Bold">Digestive System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">liver fatty deposit</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. </p>
<p><span class="Bold">Hemic and Lymphatic System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>. </p>
<p><span class="Bold">Metabolic and Nutritional </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>, creatinine increased, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>. </p>
<p><span class="Bold">Musculoskeletal System </span>— <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. </p>
<p><span class="Bold">Nervous System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, buccoglossal syndrome, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, withdrawal syndrome. </p>
<p><span class="Bold">Respiratory System </span>— <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawn</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>. </p>
<p><span class="Bold">Skin and Appendages </span>— <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, pruritis; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>. </p>
<p><span class="Bold">Special Senses </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">abnormality of accommodation</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>. </p>
<p><span class="Bold">Urogenital System </span>— <span class="Italics">Frequent: </span><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span><span class="Sup">2</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>; <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span><span class="Sup">2</span>, female lactation<span class="Sup">2</span>, <span class="product-label-link" type="condition" conceptid="4275882" conceptname="Hypomenorrhea">hypomenorrhea</span><span class="Sup">2</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span><span class="Sup">2</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">urination impaired</span>; <span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="80478" conceptname="Engorgement of breasts associated with childbirth">breast engorgement</span><span class="Sup">2</span>.</p>
<p><span class="Sup">1</span>This term represents a serious adverse event but does not meet the definition for adverse drug reactions. It is included here because of its seriousness. </p>
<p><span class="Sup">2</span>Adjusted for gender.</p>
<p><span class="Underline">Other Adverse Reactions Observed with Olanzapine or Fluoxetine Monotherapy </span></p>
<p>The following adverse reactions were not observed in olanzapine and fluoxetine HCl -treated patients during premarketing clinical studies but have been reported with olanzapine or fluoxetine monotherapy: <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="4099943" conceptname="Bruxism">bruxism</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4095288" conceptname="Diabetic coma with ketoacidosis">diabetic coma</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonia</span> <span class="Sup">3</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, espohgeal <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>, gynecological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, sudden unexpected <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">3</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span><span class="Sup">3</span>. Random triglyceride levels of ≥1000 mg/dL have been reported. </p>
<p><span class="Sup">3</span>These terms represent serious adverse events but do not meet the definition for adverse drug reactions. They are included here because of their seriousness. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-5ee2de85-1612-42ef-843b-cefd9a71c02b"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Vital Signs and Laboratory Studies </h2>
<p class="First"><span class="Underline">Vital Signs </span>— <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> have occurred in olanzapine and fluoxetine HCl -treated patients <span class="Italics">[see Warnings and Precautions (<a href="#inv-66597682-6f74-44e5-9c0e-69b9d506a574">5.11</a>)]</span>. The mean standing pulse rate of olanzapine and fluoxetine HCl -treated patients was reduced by 0.7 beats/min. </p>
<p><span class="Underline">Laboratory Changes </span>— In olanzapine and fluoxetine HCl clinical studies, olanzapine and fluoxetine HCl was associated with statistically significantly greater frequencies for the following treatment-emergent findings in laboratory analytes (normal at baseline to abnormal at any time during the trial) compared to placebo: elevated prolactin (28% vs 5%); elevated urea nitrogen (3% vs 0.8%); elevated uric acid (3% vs 0.5%); low albumin (3% vs 0.3%); low <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (14% vs 9%); low hemoglobin (3% vs 0%); low inorganic phosphorus (2% vs 0.3%); low <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> (2% vs 0%); and low total bilirubin (15% vs 4%). </p>
<p>As with olanzapine, asymptomatic elevations of hepatic aminotransferases [ALT, AST, and GGT] and alkaline phosphatase have been observed with olanzapine and fluoxetine HCl. In the olanzapine and fluoxetine HCl -controlled database, clinically significant ALT elevations (change from &lt;3 times the upper limit of normal [ULN] at baseline to ≥3 times ULN) were observed in 5% (38/698) of patients exposed to olanzapine and fluoxetine HCl compared with 0.5% (2/378) of placebo-treated patients and 4% (33/751) of olanzapine-treated patients. ALT elevations ≥5 times ULN were observed in 2% (11/701 of olanzapine and fluoxetine HCl-treated patients, compared to 0.3% (1/379) of placebo-treated patients and 1% (11/760) of olanzapine-treated patients. No patient with elevated ALT values experienced <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, or met the criteria for Hy’s Rule. ALT values returned to normal, or were decreasing, at last follow-up in the majority of patients who either continued treatment with olanzapine and fluoxetine HCl or discontinued olanzapine and fluoxetine HCl.</p>
<p>Rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been received in patients treated with olanzapine. Very rare cases of cholestatic or mixed <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have also been reported in the postmarketing period in patients treated with olanzapine.</p>
<p>Caution should be exercised in patients with signs and symptoms of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs.</p>
<p>An increase in creatine phosphokinase has been reported very rarely in olanzapine and fluoxetine HCl-treated patients and infrequently in clinical trials of olanzapine-treated patients.</p>
<p><span class="Underline">Effect on Cardiac Repolarization </span>— The mean increase in QT<span class="Sub">c</span> interval for olanzapine and fluoxetine HCl-treated patients (4.4 msec) in clinical studies was significantly greater than that for placebo-treated (-0.8 msec), olanzapine-treated (-0.3 msec) patients, and fluoxetine treated (1.7 msec) patients. There were no significant differences between patients treated with olanzapine and fluoxetine HCl, placebo, olanzapine, or fluoxetine in the incidence of QT<span class="Sub">c</span> outliers (&gt;500 msec). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2db62d89-e21f-4af8-81a2-55353fea862d"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during post-approval use of olanzapine and fluoxetine HCl. Because these reactions are reported voluntarily from a population of uncertain size, it is difficult to reliably estimate their frequency or evaluate a causal relationship to drug exposure.</p>
<p>Adverse reactions reported since market introduction that were temporally (but not necessarily causally) related to olanzapine and fluoxetine HCl therapy include the following: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> and venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (including <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="inv-fdf702d0-a3d0-4766-9b04-7efab6a1c7d9"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS </h1>
<p class="First">The risks of using olanzapine and fluoxetine HCl in combination with other drugs have not been extensively evaluated in systematic studies. The drug-drug interactions sections of fluoxetine and olanzapine are applicable to olanzapine and fluoxetine HCl. As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.) is a possibility. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-0982aece-1997-4ea0-8959-9b67efb5870c"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Monoamine Oxidase Inhibitors (MAOI) </h2>
<p class="First"><span class="Italics">[see Dosage and Administration (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>) (2.5), Contraindications (</span><span class="Italics"><a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a></span><span class="Italics">), Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-6884cf9d-6a91-4313-bd1d-19931593879e"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CNS Acting Drugs </h2>
<p class="First">Caution is advised if the concomitant administration of olanzapine and fluoxetine HCl and other CNS-active drugs is required. In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a9a74877-c887-49d1-aecc-75936155eb81"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Serotonergic Drugs </h2>
<p class="First"><span class="Italics">[see Dosage and Administration (<a href="#inv-295990ef-2bcc-45ea-8b6f-c5d87d811633">2.4</a>) (<a href="#ID_27db6d82-35cd-467d-b7c8-7c21ff488e83">2.5</a>), Contraindications (<a href="#ID_8b78cf64-08d8-4ee0-90c7-daf27bec34b2">4.1</a>) and Warnings and Precations (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-6f7af79a-238e-4967-b17d-4a0fe651255d"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, Warfarin) </h2>
<p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SNRIs or SSRIs are coadministered with warfarin <span class="Italics">[see Warnings and Precautions (<a href="#inv-09cc51c9-342e-45cb-9784-0429d5c0b351">5.15</a>)]</span>. Warfarin (20 mg single dose) did not affect olanzapine pharmacokinetics. Single doses of olanzapine did not affect the pharmacokinetics of warfarin. Patients receiving warfarin therapy should be carefully monitored when olanzapine and fluoxetine HCl is initiated or discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-392e9e96-9e11-440a-95e8-5ee4a57a8ce3"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Electroconvulsive Therapy (ECT)</h2>
<p class="First">There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine. There have been rare reports of prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in patients on fluoxetine receiving ECT treatment <span class="Italics">[see Warnings and Precautions (<a href="#inv-cb14208f-4d7d-49ed-b151-fb0894fb510c">5.14</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-4d061a49-55e2-410b-b10e-760f9aa6656d"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Potential for Other Drugs to Affect Olanzapine and Fluoxetine HCl</h2>
<p class="First"><span class="Underline">Benzodiazepines </span>— Co-administration of diazepam with olanzapine potentiated the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with olanzapine <span class="Italics">[see Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. </p>
<p><span class="Underline">Inducers of 1A2 </span>— Carbamazepine therapy (200 mg BID) causes an approximate 50% increase in the clearance of olanzapine. This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity. Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance <span class="Italics">[see Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. </p>
<p><span class="Underline">Alcohol </span>— Ethanol (45 mg/70 kg single dose) did not have an effect on olanzapine pharmacokinetics <span class="Italics">[see Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. </p>
<p><span class="Underline">Inhibitors of CYP1A2 </span>— Fluvoxamine decreases the clearance of olanzapine. This results in a mean increase in olanzapine C<span class="Sub">max</span> following fluvoxamine administration of 54% in female <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> and 77% in male smokers. The mean increase in olanzapine AUC is 52% and 108%, respectively. Lower doses of the olanzapine component of olanzapine and fluoxetine HCl should be considered in patients receiving concomitant treatment with fluvoxamine. </p>
<p><span class="Underline">The Effect of Other Drugs on Olanzapine </span>— Fluoxetine, an inhibitor of CYP2D6, decreases olanzapine clearance a small amount <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. Agents that induce CYP1A2 or glucuronyl transferase enzymes, such as omeprazole and rifampin, may cause an increase in olanzapine clearance. The effect of CYP1A2 inhibitors, such as fluvoxamine and some fluoroquinolone antibiotics, on olanzapine and fluoxetine HCl has not been evaluated. Although olanzapine is metabolized by multiple enzyme systems, induction or inhibition of a single enzyme may appreciably alter olanzapine clearance. Therefore, a dosage increase (for induction) or a dosage decrease (for inhibition) may need to be considered with specific drugs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Potential for Olanzapine and Fluoxetine HCl to Affect Other Drugs</h2>
<p class="First"><span class="Underline">Pimozide </span>— Concomitant use of fluoxetine and pimozide is contraindicated. Clinical studies of pimozide with other antidepressants demonstrate an increase in drug interaction or QT<span class="Sub">c</span> prolongation. While a specific study with pimozide and fluoxetine has not been conducted, the potential for drug interactions or QT<span class="Sub">c</span> prolongation warrants restricting the concurrent use of pimozide and fluoxetine. <span class="Italics">[See Contraindications (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>)]</span>. </p>
<p><span class="Underline">Carbamazepine </span>— Patients on stable doses of carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">anticonvulsant toxicity</span> following initiation of concomitant fluoxetine treatment.</p>
<p><span class="Underline">Alcohol </span>— The coadministration of ethanol with olanzapine and fluoxetine HCl may potentiate sedation and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> <span class="Italics">[see Drug Interactions (<a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6</a>)]</span>.</p>
<p><span class="Underline">Thioridazine </span>— Thioridazine should not be administered with olanzapine and fluoxetine HCl or administered within a minimum of 5 weeks after discontinuation of olanzapine and fluoxetine HCl.</p>
<p>In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher C <span class="Sub">max</span> and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared with the rapid hydroxylators. The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity. Thus, this study suggests that drugs that inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels of thioridazine <span class="Italics">[see Contraindications (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>)]</span>. </p>
<p>Thioridazine administration produces a dose-related prolongation of the QT <span class="Sub">c</span> interval, which is associated with serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, such as <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>. This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism <span class="Italics">[see Contraindications (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>)]</span>. </p>
<p>Due to the risk of serious <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> potentially associated with elevated thioridazine plasma levels, thioridazine should not be administered with fluoxetine or within a minimum of 5 weeks after fluoxetine has been discontinued <span class="Italics">[see Contraindications (<a href="#inv-9a42d0cc-993b-417a-b9c5-84e26819d16e">4</a>)]</span>. </p>
<p><span class="Underline">Tricyclic Antidepressants (TCAs) </span>— Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.</p>
<p>In 2 fluoxetine studies, previously stable plasma levels of imipramine and desipramine have increased &gt;2-to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCA may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when olanzapine and fluoxetine HCl is coadministered or has been recently discontinued <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. </p>
<p><span class="Underline">Antihypertensive Agents </span>— Because of the potential for olanzapine to induce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, olanzapine and fluoxetine HCl may enhance the effects of certain antihypertensive agents <span class="Italics">[see Warnings and Precautions (<a href="#inv-66597682-6f74-44e5-9c0e-69b9d506a574">5.11</a>)]</span>. </p>
<p><span class="Underline">Levodopa and Dopamine Agonists </span>— The olanzapine component of olanzapine and fluoxetine HCl may antagonize the effects of levodopa and dopamine agonists. </p>
<p><span class="Underline">Benzodiazepines </span>— Multiple doses of olanzapine did not influence the pharmacokinetics of diazepam and its active metabolite N desmethyldiazepam.</p>
<p>When concurrently administered with fluoxetine, the half-life of diazepam may be prolonged in some patients <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels. </p>
<p><span class="Underline">Clozapine </span>— Elevation of blood levels of clozapine has been observed in patients receiving concomitant fluoxetine. </p>
<p><span class="Underline">Haloperidol </span>— Elevation of blood levels of haloperidol has been observed in patients receiving concomitant fluoxetine. </p>
<p><span class="Underline">Phenytoin </span>— Patients on stable doses of phenytoin have developed elevated plasma levels of phenytoin with clinical phenytoin toxicity following initiation of concomitant fluoxetine. </p>
<p><span class="Underline">Drugs Metabolized by CYP2D6 </span>— <span class="Italics">In vitro</span> studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP2D6. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by this enzyme. </p>
<p>Fluoxetine inhibits the activity of CYP2D6 and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer. Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for a decreased dose of the original medication should be considered. Drugs with a narrow therapeutic index represent the greatest concern (including but not limited to, flecainide, propafenone, vinblastine, and TCAs).</p>
<p><span class="Underline">Drugs Metabolized by CYP3A </span>— <span class="Italics">In vitro</span> studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP3A. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes. </p>
<p>In an <span class="Italics">in vivo</span> interaction study involving the coadministration of fluoxetine with single doses of terfenadine (a CYP3A substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. In addition, <span class="Italics">in vitro</span> studies have shown ketoconazole, a potent inhibitor of CYP3A activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam. These data indicate that fluoxetine's extent of inhibition of CYP3A activity is not likely to be of clinical significance. </p>
<p><span class="Underline">Effect of Olanzapine on Drugs Metabolized by Other CYP Enzymes </span>— <span class="Italics">In vitro</span> studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, and CYP2C19. Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes. </p>
<p><span class="Underline">Lithium </span>— Multiple doses of olanzapine did not influence the pharmacokinetics of lithium. </p>
<p>There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> and increased serotonergic effects have been reported. Lithium levels should be monitored in patients taking olanzapine and fluoxetine HCl concomitantly with lithium.</p>
<p><span class="Underline">Drugs Tightly Bound to Plasma Proteins </span>— The <span class="Italics">in vitro</span> binding of olanzapine and fluoxetine HCl to human plasma proteins is similar to the individual components. The interaction between olanzapine and fluoxetine HCl and other highly protein-bound drugs has not been fully evaluated. Because fluoxetine is tightly bound to plasma protein, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely, adverse effects may result from displacement of protein-bound fluoxetine by other tightly bound drugs <span class="Italics">[see Clinical Pharmacology (<a href="#inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3">12.3</a>)]</span>. </p>
<p><span class="Underline">Valproate </span>— <span class="Italics">In vitro</span> studies using human liver microsomes determined that olanzapine has little potential to inhibit the major metabolic pathway, glucuronidation, of valproate. Further, valproate has little effect on the metabolism of olanzapine <span class="Italics">in vitro</span>. Thus, a clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> between olanzapine and valproate is unlikely. </p>
<p><span class="Underline">Biperiden </span>— Multiple doses of olanzapine did not influence the pharmacokinetics of biperiden.</p>
<p><span class="Underline">Theophylline </span>— Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.</p>
<p>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="inv-ddeafb58-845d-4547-bee7-16c339bef9f8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS </h1>
<div class="Section" data-sectionCode="42228-7">
<a name="inv-5a072cea-4133-49ad-b1d5-5efb495ce19f"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy </h2>
<p class="First"><span class="Underline">Pregnancy Category C</span></p>
<p><span class="Bold">Olanzapine and Fluoxetine HCl </span>– Olanzapine and fluoxetine HCl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, taking into account the risk of untreated Bipolar I <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>. <span class="Italics">[see fluoxetine safety information under Treatment of Pregnant Women during the First Trimester and Clinical Considerations below.]</span></p>
<p>Teratogenic Effects</p>
<p><span class="Italics">Animal Data </span>— Animal Data — Embryo fetal development studies were conducted in rats and rabbits with olanzapine and fluoxetine in low-dose and high-dose combinations. In rats, the doses were: 2 and 4 mg/kg/day (low-dose) [1 and 0.5 times the maximum recommended human dose (MRHD) for olanzapine (20 mg) and fluoxetine (80 mg), respectively, on a mg/m2 body surface area], and 4 and 8 mg/kg/day (high-dose) [2 and 1 times the MRHD on a mg/m2 body surface area, respectively]. In rabbits, the doses were 4 and 4 mg/kg/day (low-dose) [4 and 1 times the MRHD on a mg/m<span class="Sup">2 </span>basis, respectively], and 8 and 8 mg/kg/day (high-dose) [9 and 2 times the MRHD on a mg/m<span class="Sup">2</span> basis, respectively]. In these studies, olanzapine and fluoxetine were also administered alone at the high-doses (4 and 8 mg/kg/day, respectively, in the rat; 8 and 8 mg/kg/day, respectively, in the rabbit). In the rabbit, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>; however, the high-dose combination produced decreases in fetal weight and retarded skeletal ossification in conjunction with maternal toxicity. Similarly, in the rat there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>; however, a decrease in fetal weight was observed with the high-dose combination.</p>
<p>In a pre-and postnatal study conducted in rats, olanzapine and fluoxetine were orally administered during pregnancy and throughout lactation in combination at dose levels up to 2 (olanzapine) plus 4 (fluoxetine) mg/kg/day (1 and 0.5 times the MRHD on a mg/m <span class="Sup">2 </span>body surface area.  An elevation of early postnatal mortality (survival through postnatal day 4 was 69% per litter) and reduced bodyweight (approximately 8% in females) occurred among offspring at the highest dose: the no-effect dose was 0.5 (olanzapine) plus 1 (floxetine) mg/kg/day (0.25 and 0.13 times the MRHD on a mg/m<span class="Sup">2 </span>body surface area).  Among the surviving progeny, there were no adverse effects on physical or neurobehavioral development and reproductive performance at any dose. </p>
<p><span class="Bold">Olanzapine </span>— In oral reproduction studies in rats at doses up to 18 mg/kg/day and in rabbits at doses up to 30 mg/kg/day (9 and 30 times the MRHD on a mg/m<span class="Sup">2 </span>basis, respectively), no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. In a rat teratology study, early resorptions and increased numbers of nonviable fetuses were observed at a dose of 18 mg/kg/day (9 times the MRHD on a mg/m<span class="Sup">2 </span>basis). Gestation was prolonged at 10 mg/kg/day (5 times the MRHD on a mg/m<span class="Sup">2 </span>basis). In a rabbit teratology study, fetal toxicity (manifested as increased resorptions and decreased fetal weight) occurred at a maternally toxic dose of 30 mg/kg/day (30 times the MRHD on a mg/m<span class="Sup">2 </span>basis). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>Placental transfer of olanzapine occurs in rat pups.</p>
<p>There are no adequate and well-controlled clinical studies with olanzapine in pregnant women. Seven pregnancies were observed during premarketing clinical studies with olanzapine, including 2 resulting in normal births, 1 resulting in neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a cardiovascular defect, 3 therapeutic abortions, and 1 <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span>.</p>
<p><span class="Bold">Fluoxetine</span> — </p>
<p><span class="Italics">Treatment of Pregnant Women during the First Trimester – </span>There are no adequate and well-controlled clinical studies on the use of fluoxetine in pregnant women. Results of a number of published epidemiological studies assessing the risk of fluoxetine exposure during the first trimester of pregnancy have demonstrated inconsistent results. More than 10 cohort studies and case-control studies failed to demonstrate an increased risk for congenital malformations overall. However, one prospective cohort study conducted by the European Network of Teratology Information Services reported an increased risk of cardiovascular malformations in infants born to women (N – 253) exposed to fluoxetine during the first trimester of pregnancy compared to infants of women (N = 1359) who were not exposed to fluoxetine. There was no specific pattern of cardiovascular malformations. Overall, however, a causal relationship has not been established.</p>
<p><span class="Italics">Animal Data - </span>In embryo-fetal development studies in rats and rabbits, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> following administration fluoxetine at doses up to 12.5 and 15 mg/kg/day, respectively (1.5 and 3.6 times, respectively, the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2</span> basis) throughout organogenesis. However, in rat reproduction studies, an increase in stillborn pups, a decrease in pup weight, and an increase in pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the first 7 days postpartum occurred following maternal exposure to 12 mg/kg/day (1.5 times the MRHD on a mg/ m<span class="Sup">2 </span>basis) during gestation or 7.5 mg/kg/day (0.9 times the MRHD on a mg/m<span class="Sup">2 </span>basis) during gestation and lactation. There was no evidence of developmental <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">neurotoxicity</span> in the surviving offspring of rats treated with 12 mg/kg/day during gestation. The no-effect dose for rat pup mortality was 5 mg/kg/day (0.6 times the MRHD on a mg/m<span class="Sup">2 </span>basis). </p>
<p><span class="Underline">Nonteratogenic Effects</span></p>
<p>Neonates exposed to fluoxetine, a component of olanzapine and fluoxetine, and other SSRIs  or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>), and Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>).]</span>. </p>
<p>Infants exposed to SSRIs in pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). PPHN occurs in 1 to 2 per 1000 live births in the general population and is associated with substantial neonatal morbidity and mortality. Several recent epidemiologic studies suggest a positive statistical association between SSRI (including fluoxetine) use in pregnancy and PPHN. Other studies do not show a significant statistical association. </p>
<p>Physicians should also note the results of a prospective longitudinal study of 201 pregnant women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span>, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission. Women who discontinued antidepressant medication during pregnancy showed a significant increase in relapse of their <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> compared to those women who remained on antidepressant medication throughout pregnancy.</p>
<p>Neonates exposed to antipsychotic drugs (including olanzapine), during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>When treating pregnant women with olanzapine and fluoxetine, the physician should carefully consider both the potential risks of taking and SSRI, along with established benefits of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with an antidepressant. This decision can only be made on a case by case basis <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="inv-78e83418-b1eb-495f-ac11-004a31df7a0d"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery </h2>
<p class="First"><span class="Bold">Olanzapine and Fluoxetine HCl </span>— The effect of olanzapine and fluoxetine HCl on labor and delivery in humans is unknown. Parturition in rats was not affected by olanzapine and fluoxetine HCl. Olanzapine and fluoxetine HCl should be used during labor and delivery only if the potential benefit justifies the potential risk. </p>
<p><span class="Bold">Olanzapine </span>— The effect of olanzapine on labor and delivery in humans is unknown. Parturition in rats was not affected by olanzapine. </p>
<p><span class="Bold">Fluoxetine </span>— The effect of fluoxetine on labor and delivery in humans is unknown. Fluoxetine crosses the placenta; therefore, there is a possibility that fluoxetine may be associated with adverse effects on the newborn. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="inv-d9a8afb7-28df-4930-b228-7c2e43925ffe"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers </h2>
<p class="First"><span class="Bold">Olanzapine and Fluoxetine HCl</span> — Studies evaluating the individual components of olanzapine and fluoxetine HCl in nursing mothers are described below. Because of the potential for serious adverse reactions in nursing infants from olanzapine and fluoxetine HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. It is recommended that women not breast-feed when receiving olanzapine and fluoxetine HCl. </p>
<p><span class="Bold">Olanzapine </span>— In a study in lactating, healthy women, olanzapine was excreted in breast milk. Mean infant dose at steady-state was estimated to be 1.8% of the maternal olanzapine dose. It is recommended that women receiving olanzapine should not breast-feed. </p>
<p><span class="Bold">Fluoxetine </span>— Fluoxetine is excreted in human breast milk. In 1 breast milk sample, the concentration of fluoxetine plus norfluoxetine was 70.4 ng/mL. The concentration in the mother's plasma was 295.0 ng/mL. No adverse effects on the infant were reported. In another case, an infant nursed by a mother on fluoxetine developed <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and watery stools. The infant's plasma drug levels were 340 ng/mL of fluoxetine and 208/mL of norfluoxetine on the 2nd day of feeding. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="inv-a983ce35-3e93-4317-8735-fb289171fd06"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First"><span class="Bold">Olanzapine and Fluoxetine </span>— Safety and effectiveness in children and adolescent patients have not been established. Anyone considering the use of olanzapine and fluoxetine HCl in a child or adolescent must balance the potential risks with the clinical need <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>)]</span>.</p>
<p>Safety and effectiveness of olanzapine and fluoxetine in combination in children and adolescents &lt;18 years of age have not been established.</p>
<p><span class="Bold">Olanzapine</span> – Safety and effectiveness of olanzapine in children &lt;13 years of age have not been established. </p>
<p>Compared to patients from adult clinical trials, adolescents treated with oral olanzapine were likely to gain more weight, experience increased sedation, and have greater increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, prolactin and hepatic aminotransferase levels.</p>
<p><span class="Bold">Fluoxetine </span>— Significant toxicity, including myotoxicity, long-term neurobehavioral and reproductive toxicity, and impaired bone development, has been observed following exposure of juvenile animals to fluoxetine. Some of these effects occurred at clinically relevant exposures. </p>
<p>In a study in which fluoxetine (3, 10, or 30 mg/kg) was orally administered to young rats from weaning (Postnatal Day 21) through adulthood (Day 90), male and female sexual development was delayed at all doses, and growth (body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, femur length) was decreased during the dosing period in animals receiving the highest dose. At the end of the treatment period, serum levels of creatine kinase (marker of <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span>) were increased at the intermediate and high doses, and abnormal muscle and reproductive organ histopathology (skeletal <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle degeneration</span> and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, testicular degeneration and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, epididymal vacuolation and hypospermia) was observed at the high dose. When animals were evaluated after a recovery period (up to 11 weeks after cessation of dosing), neurobehavioral abnormalities (decreased reactivity at all doses and learning deficit at the high dose) and reproductive functional impairment (decreased mating at all doses and impaired fertility at the high dose) were seen; in addition, testicular and epididymal microscopic lesions and decreased sperm concentrations were found in the high dose group, indicating that the reproductive organ effects seen at the end of treatment were irreversible. The reversibility of fluoxetine-induced <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> was not assessed. Adverse effects similar to those observed in rats treated with fluoxetine during the juvenile period have not been reported after administration of fluoxetine to adult animals. Plasma exposures (AUC) to fluoxetine in juvenile rats receiving the low, intermediate, and high dose in this study were approximately 0.1 to 0.2, 1 to 2, and 5 to 10 times, respectively, the average exposure in pediatric patients receiving the maximum recommended dose (MRD) of 20 mg/day. Rat exposures to the major metabolite, norfluoxetine, were approximately 0.3 to 0.8, 1 to 8, and 3 to 20 times, respectively, pediatric exposure at the MRD.</p>
<p>A specific effect of fluoxetine on bone development has been reported in mice treated with fluoxetine during the juvenile period. When mice were treated with fluoxetine (5 or 20 mg/kg, intraperitoneal) for 4 weeks starting at 4 weeks of age, bone formation was reduced resulting in decreased bone mineral content and density. These doses did not affect overall growth (body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or femoral length). The doses administered to juvenile mice in this study are approximately 0.5 and 2 times the MRD for pediatric patients on a body surface area (mg/m <span class="Sup">2</span>) basis. </p>
<p>In another mouse study, administration of fluoxetine (10 mg/kg intraperitoneal) during early postnatal development (Postnatal Days 4 to 21) produced abnormal emotional behaviors (decreased exploratory behavior in elevated plus-maze, increased <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> avoidance latency) in adulthood (12 weeks of age). The dose used in this study is approximately equal to the pediatric MRD on a mg/m <span class="Sup">2 </span>basis. Because of the early dosing period in this study, the significance of these findings to the approved pediatric use in humans is uncertain. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="inv-592f745a-0a5f-4fc0-aac0-084a49716dae"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use </h2>
<p class="First"><span class="Bold">Olanzapine and Fluoxetine </span>— Clinical studies of olanzapine and fluoxetine HCl did not include sufficient numbers of patients ≥65 years of age to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)]</span>. </p>
<p><span class="Bold">Olanzapine </span>— Of the 2500 patients in premarketing clinical studies with olanzapine, 11% (263 patients) were ≥65 years of age. In patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>, there was no indication of any different tolerability of olanzapine in the elderly compared with younger patients. Studies in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> have suggested that there may be a different tolerability profile in this population compared with younger patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>. Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with olanzapine are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo. In placebo-controlled studies of olanzapine in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, there was a higher incidence of cerebrovascular adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Boxed Warning, Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>), and Warnings and Precautions (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>)]</span>. </p>
<p>Also, the presence of factors that might decrease pharmacokinetic clearance or increase the pharmacodynamic response to olanzapine should lead to consideration of a lower starting dose for any geriatric patient.</p>
<p><span class="Bold">Fluoxetine </span>— U.S. fluoxetine clinical studies included 687 patients ≥65 years of age and 93 patients ≥75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. SNRIs and SSRIs, including olanzapine and fluoxetine HCl, have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse reaction <span class="Italics">[see Warnings and Precautions (<a href="#inv-9e6d3f5a-bb88-4467-af87-c86e9acdf898">5.16</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f94d8c73-26be-46d4-a323-00d45eac781e"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">In subjects with cirrhosis of the liver, the clearances of fluoxetine and its active metabolite, norfluoxetine, were decreased, thus increasing the elimination half-lives of these substances. A lower or less frequent dose of the fluoxetine-component of olanzapine and fluoxetine HCl should be used in patients with cirrhosis. Caution is advised when using olanzapine and fluoxetine HCl in patients with diseases or conditions that could affect its metabolism <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>) and Clinical Pharmacology (<a href="#inv-8423052d-ce2b-47a2-9ef2-b47e30cb1fc4">12.4</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="inv-74d3eec5-dfc2-4940-84fb-df74bd04ef0c"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </h1>
<div class="Section" data-sectionCode="34087-7">
<a name="inv-195c9df2-9f49-4afd-b7d0-db9ec61155c9"></a><a name="section-9.1"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Olanzapine and fluoxetine HCl, as with fluoxetine and olanzapine, has not been systematically studied in humans for its potential for abuse, tolerance, or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. While the clinical studies did not reveal any tendency for any drug-seeking behavior, these observations were not systematic, and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of olanzapine and fluoxetine HCl (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).</p>
<p>In studies in rats and rhesus monkeys designed to assess abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential, olanzapine alone was shown to have acute depressive CNS effects but little or no potential of abuse or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> at oral doses up to 15 (rat) and 8 (monkey) times the MRHD (20 mg) on a mg/m <span class="Sup">2</span> basis. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="inv-e69aceed-b284-4d29-aa7f-dea3f02cde38"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE </h1>
<p class="First"><span class="Bold">Olanzapine and Fluoxetine HCl </span>— During premarketing clinical studies of olanzapine and fluoxetine in combination, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of both fluoxetine and olanzapine were reported in 5 study subjects. Four of the 5 subjects experienced <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (3) or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> (1). No fatalities occurred. </p>
<p>Adverse reactions involving <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of fluoxetine and olanzapine in combination, and olanzapine and fluoxetine HCl, have been reported. An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of combination therapy is defined as confirmed or suspected ingestion of a dose of &gt;20 mg olanzapine in combination with a dose of &gt;80 mg fluoxetine. Adverse reactions associated with these reports included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (sedation), impaired consciousness (<span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), impaired neurologic function (<span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>), <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="43531003" conceptname="Essential tremor">essential tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, acute <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>. Fatalities have been confounded by exposure to additional substances including alcohol, thioridazine, oxycodone, and propoxyphene.</p>
<p><span class="Bold">Olanzapine </span>— In postmarketing reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with olanzapine alone, symptoms have been reported in the majority of cases. In symptomatic patients, symptoms with ≥10% incidence included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>/<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, various <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and reduced level of consciousness ranging from sedation to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. Among less commonly reported symptoms were the following potentially medically serious reactions: <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> (such as <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> as well as a patient that experienced sinus pause with spontaneous resumption of normal rhythm), <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, possible <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>/arrest, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. There have been reports of fatality in association with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of olanzapine alone. In 1 case of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, the amount of acutely ingested olanzapine was reported to be possibly as low as 450 mg of oral olanzapine; however, in another case, a patient was reported to survive an acute olanzapine ingestion of approximately 2 g of oral olanzapine. </p>
<p><span class="Bold">Fluoxetine </span>— Worldwide exposure to fluoxetine is estimated to be over 38 million patients (circa 1999). Of the 1578 cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving fluoxetine, alone or with other drugs, reported from this population, there were 195 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. </p>
<p>Among 633 adult patients who overdosed on fluoxetine alone, 34 resulted in a fatal outcome, 378 completely recovered, and 15 patients experienced sequelae after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, including abnormal accommodation, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, unresponsiveness, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, pulmonary dysfunction, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, elevated blood pressure, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. The remaining 206 patients had an unknown outcome. The most common signs and symptoms associated with non-fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> were <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The largest known ingestion of fluoxetine in adult patients was 8 grams in a patient who took fluoxetine alone and who subsequently recovered. However, in an adult patient who took fluoxetine alone, an ingestion as low as 520 mg has been associated with lethal outcome, but causality has not been established.</p>
<p>Among pediatric patients (ages 3 months to 17 years), there were 156 cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving fluoxetine alone or in combination with other drugs. Six patients died, 127 patients completely recovered, 1 patient experienced <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and 22 patients had an unknown outcome. One of the 6 fatalities was a 9-year-old boy who had a history of OCD, Tourette's Syndrome with <span class="product-label-link" type="condition" conceptid="4297396" conceptname="Tic">tics</span>, <span class="product-label-link" type="condition" conceptid="4149353" conceptname="Attention deficit hyperactivity disorder, predominantly inattentive type">attention deficit disorder</span>, and fetal alcohol syndrome. He had been receiving 100 mg of fluoxetine daily for 6 months in addition to clonidine, methylphenidate, and promethazine. Mixed-drug ingestion or other methods of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> complicated all 6 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in children that resulted in fatalities. The largest ingestion in pediatric patients was 3 grams, which was non-lethal.</p>
<p>Other important adverse reactions reported with fluoxetine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (single or multiple drugs) included <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, ECG abnormalities (such as QT-interval prolongation and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>-like reactions, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-115106f2-ed37-4d2b-91f8-fdbf22dfbf01"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> </h2>
<p class="First">In managing <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the possibility of multiple drug involvement should be considered. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, establish and maintain an airway and ensure adequate ventilation, which may include intubation. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended as the possibility of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> of the head and neck following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may create a risk for <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. Gastric lavage (after intubation, if patient is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>) and administration of activated charcoal together with a laxative should be considered. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p>A specific precaution involves patients who are taking or have recently taken olanzapine and fluoxetine HCl and may have ingested excessive quantities of a TCA (tricyclic antidepressant). In such cases, accumulation of the parent TCA and/or an active metabolite may increase the possibility of serious sequelae and extend the time needed for close medical observation.</p>
<p>Due to the large volume of distribution of olanzapine and fluoxetine, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidote for either fluoxetine or olanzapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is known. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. Do not use epinephrine, dopamine, or other sympathomimetics with β-agonist activity, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of olanzapine-induced alpha blockade.</p>
<p>The physician should consider contacting a poison control center for additional information on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference (PDR)</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="inv-1f8ac05b-05ec-41d7-88f2-70c6efcf1c65"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION </h1>
<p class="First">Olanzapine and fluoxetine capsules USP combines an atypical antipsychotic and a selective serotonin reuptake inhibitor, olanzapine (the active ingredient in Zyprexa <span class="Sup">®*</span>, and Zyprexa Zydis<span class="Sup">®*</span>) and fluoxetine hydrochloride (the active ingredient in Prozac<span class="Sup">®</span>*, Prozac Weekly<span class="Sup">™*</span>, and Sarafem<span class="Sup">®*</span>).</p>
<p>Olanzapine belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10 <span class="Italics">H</span> thieno[2,3-<span class="Italics">b</span>] [1,5]benzodiazepine. The molecular formula is C<span class="Sub">17</span>H<span class="Sub">20</span>N<span class="Sub">4</span>S, which corresponds to a molecular weight of 312.44. </p>
<p>Fluoxetine hydrochloride is a selective serotonin reuptake inhibitor (SSRI). The chemical designation is (±)-N-methyl-3-phenyl-3‑[(α,α,α-trifluoro- <span class="Italics">p</span>-tolyl)oxy]propylamine hydrochloride. The molecular formula is C<span class="Sub">17</span>H<span class="Sub">18</span>F<span class="Sub">3</span>NO•HCl, which corresponds to a molecular weight of 345.79. The chemical structures are: </p>
<div class="Figure">
<a name="ID0ELXDI"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-01.jpg">
</div>
<p>Olanzapine is a yellow crystalline solid, which is practically insoluble in water.</p>
<p>Fluoxetine hydrochloride is a white to off-white crystalline solid with a solubility of 14 mg/mL in water.</p>
<p>Olanzapine and fluoxetine capsules USP are available for oral administration in the following strength combinations:</p>
<table>
<col width="59%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="12%">
<col width="12%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Toprule" valign="top"><p class="First"> 3 mg/25 mg</p></td>
<td class="Botrule Toprule" valign="top"><p class="First"> 6 mg/25 mg </p></td>
<td class="Botrule Toprule" valign="top"><p class="First"> 6 mg/50 mg</p></td>
<td class="Botrule Toprule" valign="top"><p class="First"> 12 mg/25 mg</p></td>
<td class="Botrule Rrule Toprule" valign="top"><p class="First"> 12 mg/50 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"> Olanzapine equivalent</p></td>
<td class="Botrule" valign="top"><p class="First"> 3</p></td>
<td class="Botrule" valign="top"><p class="First"> 6</p></td>
<td class="Botrule" valign="top"><p class="First"> 6</p></td>
<td class="Botrule" valign="top"><p class="First"> 12</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 12</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First"> Fluoxetine base 	equivalent</p></td>
<td class="Botrule" valign="top"><p class="First"> 25</p></td>
<td class="Botrule" valign="top"><p class="First"> 25</p></td>
<td class="Botrule" valign="top"><p class="First"> 50</p></td>
<td class="Botrule" valign="top"><p class="First"> 25</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> 50</p></td>
</tr>
</tbody>
</table>
<p>Each capsule consists of gelatin, magnesium stearate, partially pregelatinized starch, titanium dioxide, and yellow iron oxide. In addition, the 3 mg/25 mg capsule also contains red iron oxide; the 6 mg/50 mg capsule also contains FD&amp;C blue No. 2, FD&amp;C red No. 3, and FD&amp;C yellow No. 6; the 12 mg/25 mg capsule also contains D&amp;C red No. 28, FD&amp;C blue No. 1, FD&amp;C red No. 40, and red iron oxide; and the 12 mg/50 mg capsule also contains D&amp;C red No. 28, FD&amp;C blue No. 1 FD&amp;C blue No. 2, FD&amp;C red No. 3, FD&amp;C red No. 40, and FD&amp;C yellow No. 6. The capsules also have printing in edible black ink which contains the following ingredients: D&amp;C yellow No. 10, ethanol, FD&amp;C blue No. 1, FD&amp;C blue No. 2, FD&amp;C red No. 40, iron oxide black, methanol, n-Butyl alcohol, propylene glycol, and shellac glaze in alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="inv-e4600228-094c-40eb-bf2f-493f864f6591"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY </h1>
<div class="Section" data-sectionCode="43679-0">
<a name="inv-318b3b0e-dea5-4aa3-acce-7d50ee6fc1e4"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action </h2>
<p class="First">Although the exact mechanism of olanzapine and fluoxetine HCl is unknown, it has been proposed that the activation of 3 monoaminergic neural systems (serotonin, norepinephrine, and dopamine) is responsible for its enhanced antidepressant effect. In animal studies, ZYPREXA and fluoxetine in combination has been shown to produce synergistic increases in norepinephrine and dopamine release in the prefrontal cortex compared with either component alone, as well as increases in serotonin.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="inv-c8a885be-32a6-431d-93ff-27fb6ec647b4"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics </h2>
<p class="First">Olanzapine binds with high affinity to the following receptors: serotonin 5HT <span class="Sub">2A/2C</span>, 5HT<span class="Sub">6</span> (K<span class="Sub">i</span>=4, 11, and 5 nM, respectively), dopamine D<span class="Sub">1-4</span> (K<span class="Sub">i</span>=11 to 31 nM), histamine H<span class="Sub">1</span> (K<span class="Sub">i</span>=7 nM), and adrenergic α<span class="Sub">1</span> receptors (K<span class="Sub">i</span>=19 nM). Olanzapine is an antagonist with moderate affinity binding for serotonin 5HT<span class="Sub">3</span> (K<span class="Sub">i</span>=57 nM) and muscarinic M<span class="Sub">1-5</span> (K<span class="Sub">i</span>=73, 96, 132, 32, and 48 nM, respectively). Olanzapine binds weakly to GABA<span class="Sub">A</span>, BZD, and β-adrenergic receptors (K<span class="Sub">i</span>&gt;10 µM). Fluoxetine is an inhibitor of the serotonin transporter and is a weak inhibitor of the norepinephrine and dopamine transporters.</p>
<p>Antagonism at receptors other than dopamine and 5HT <span class="Sub">2</span> may explain some of the other therapeutic and side effects of olanzapine. Olanzapine's antagonism of muscarinic M<span class="Sub">1-5</span> receptors may explain its anticholinergic-like effects. The antagonism of histamine H<span class="Sub">1</span> receptors by olanzapine may explain the <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> observed with this drug. The antagonism of α<span class="Sub">1</span>-adrenergic receptors by olanzapine may explain the <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> observed with this drug. Fluoxetine has relatively low affinity for muscarinic, α<span class="Sub">1</span>-adrenergic, and histamine H<span class="Sub">1</span> receptors.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="inv-ec61697b-30fc-476e-a3ab-efc7e22c32e3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<p class="First"><span class="Bold">Olanzapine and fluoxetine HCl </span>— Fluoxetine (administered as a 60 mg single dose or 60 mg daily for 8 days) caused a small increase in the mean maximum concentration of olanzapine (16%) following a 5 mg dose, an increase in the mean area under the curve (17%) and a small decrease in mean apparent clearance of olanzapine (16%). In another study, a similar decrease in apparent clearance of olanzapine of 14% was observed following olanzapine doses of 6 or 12 mg with concomitant fluoxetine doses of 25 mg or more. The decrease in clearance reflects an increase in bioavailability. The terminal half-life is not affected, and therefore the time to reach steady state should not be altered. The overall steady-state plasma concentrations of olanzapine and fluoxetine when given as the combination in the therapeutic dose ranges were comparable with those typically attained with each of the monotherapies. The small change in olanzapine clearance, observed in both studies, likely reflects the inhibition of a minor metabolic pathway for olanzapine via CYP2D6 by fluoxetine, a potent CYP2D6 inhibitor, and was not deemed clinically significant. Therefore, the pharmacokinetics of the individual components is expected to reasonably characterize the overall pharmacokinetics of the combination. </p>
<p><span class="Underline">Absorption and Bioavailability </span></p>
<p><span class="Bold">Olanzapine and fluoxetine HCl </span>— Following a single oral 12 mg/50 mg dose of olanzapine and fluoxetine HCl, peak plasma concentrations of olanzapine and fluoxetine occur at approximately 4 and 6 hours, respectively. The effect of food on the absorption and bioavailability of olanzapine and fluoxetine HCl has not been evaluated. The bioavailability of olanzapine given as Zyprexa, and the bioavailability of fluoxetine given as Prozac were not affected by food. It is unlikely that there would be a significant food effect on the bioavailability of olanzapine and fluoxetine HCl. </p>
<p><span class="Bold">Olanzapine </span>— Olanzapine is well absorbed and reaches peak concentration approximately 6 hours following an oral dose. Food does not affect the rate or extent of olanzapine absorption when olanzapine is given as Zyprexa. It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. </p>
<p><span class="Bold">Fluoxetine </span>— Following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours. Food does not appear to affect the systemic bioavailability of fluoxetine given as Prozac, although it may delay its absorption by 1 to 2 hours, which is probably not clinically significant. </p>
<p><span class="Underline">Distribution </span></p>
<p><span class="Bold">Olanzapine and Fluoxetine </span>— The <span class="Italics">in vitro</span> binding to human plasma proteins of olanzapine and fluoxetine in combination is similar to the binding of the individual components. </p>
<p><span class="Bold">Olanzapine </span>— Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L. It is 93% bound to plasma proteins over the concentration range of 7 to 1100 ng/mL, binding primarily to albumin and α<span class="Sub">1</span>-acid glycoprotein. </p>
<p><span class="Bold">Fluoxetine </span>— Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound <span class="Italics">in vitro</span> to human serum proteins, including albumin and α<span class="Sub">1</span>-glycoprotein. The interaction between fluoxetine and other highly protein-bound drugs has not been fully evaluated <span class="Italics">[see Drug Interactions (</span><span class="Italics"><a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a></span><span class="Italics">)]</span>. </p>
<p><span class="Underline">Metabolism and Elimination </span></p>
<p><span class="Bold">Olanzapine and Fluoxetine HCl </span>— Olanzapine and fluoxetine HCl therapy yielded steady state concentrations of norfluoxetine similar to those seen with fluoxetine in the therapeutic dose range. </p>
<p><span class="Bold">Olanzapine </span>— Olanzapine displays linear pharmacokinetics over the clinical dosing range. Its half-life ranges from 21 to 54 hours (5th to 95th percentile; mean of 30 hr), and apparent plasma clearance ranges from 12 to 47 L/hr (5th to 95th percentile; mean of 25 L/ hr). Administration of olanzapine once daily leads to steady state concentrations in about 1 week that are approximately twice the concentrations after single doses. Plasma concentrations, half-life, and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>) and Clinical Pharmacology (<a href="#inv-8423052d-ce2b-47a2-9ef2-b47e30cb1fc4">12.4</a>)]</span>. </p>
<p>Following a single oral dose of <span class="Sup">14</span>C-labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized. Approximately 57% and 30% of the dose was recovered in the urine and feces, respectively. In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites. After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4’-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine. Both metabolites lack pharmacological activity at the concentrations observed. </p>
<p>Direct glucuronidation and CYP450-mediated oxidation are the primary metabolic pathways for olanzapine. <span class="Italics">In vitro</span> studies suggest that CYP1A2, CYP2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation. CYP2D6-mediated oxidation appears to be a minor metabolic pathway <span class="Italics">in vivo</span>, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme. </p>
<p><span class="Bold">Fluoxetine </span>— Fluoxetine is a racemic mixture (50/50) of <span class="Italics">R</span>-fluoxetine and <span class="Italics">S</span>-fluoxetine enantiomers. In animal models, both enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity. The <span class="Italics">S</span>-fluoxetine enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state. </p>
<p>Fluoxetine is extensively metabolized in the liver to its only identified active metabolite, norfluoxetine, via the CYP2D6 pathway. A number of unidentified metabolites exist.</p>
<p>In animal models, <span class="Italics">S</span>-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to <span class="Italics">R</span>-or <span class="Italics">S</span>-fluoxetine. <span class="Italics">R</span>-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake. The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. </p>
<p><span class="Underline">Clinical Issues Related to Metabolism and Elimination </span>The complexity of the metabolism of fluoxetine has several consequences that may potentially affect the clinical use of olanzapine and fluoxetine HCl. </p>
<p><span class="Italics">Variability in Metabolism </span>— A subset (about 7%) of the population has reduced activity of the drug metabolizing enzyme CYP2D6. Such individuals are referred to as “poor metabolizers? of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants (TCAs). In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized <span class="Italics">S</span>-fluoxetine at a slower rate and thus achieved higher concentrations of <span class="Italics">S</span>-fluoxetine. Consequently, concentrations of <span class="Italics">S-</span>norfluoxetine at steady state were lower. The metabolism of <span class="Italics">R</span>-fluoxetine in these poor metabolizers appears normal. When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4 enantiomers was not significantly greater among poor metabolizers. Thus, the net pharmacodynamic activities were essentially the same. Alternative nonsaturable pathways (non-CYP2D6) also contribute to the metabolism of fluoxetine. This explains how fluoxetine achieves a steady state concentration rather than increasing without limit. </p>
<p>Because the metabolism of fluoxetine, like that of a number of other compounds including TCAs and other selective serotonin antidepressants, involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions <span class="Italics">[see Drug Interactions (<a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. </p>
<p><span class="Italics">Accumulation and Slow Elimination </span>— The relatively slow elimination of fluoxetine (elimination half-life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used. After 30 days of dosing at 40 mg/day, plasma concentrations of fluoxetine in the range of 91 to 302 ng/mL and norfluoxetine in the range of 72 to 258 ng/mL have been observed. Plasma concentrations of fluoxetine were higher than those predicted by single-dose studies, because the metabolism of fluoxetine is not proportional to dose. However, norfluoxetine appears to have linear pharmacokinetics. Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days. Steady state levels after prolonged dosing are similar to levels seen at 4 to 5 weeks. </p>
<p>The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy at discontinuation). This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of fluoxetine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8423052d-ce2b-47a2-9ef2-b47e30cb1fc4"></a><a name="section-12.4"></a><p></p>
<h2>12.4 Specific Populations </h2>
<p class="First"><span class="Underline">Geriatric </span>— Based on the individual pharmacokinetic profiles of olanzapine and fluoxetine, the pharmacokinetics of olanzapine and fluoxetine HCl may be altered in geriatric patients. Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or pharmacodynamic sensitivity. </p>
<p>In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine was about 1.5 times greater in elderly subjects (≥65 years of age) than in non-elderly subjects (&lt;65 years of age).</p>
<p>The disposition of single doses of fluoxetine in healthy elderly subjects (≥65 years of age) did not differ significantly from that in younger normal subjects. However, given the long half-life and nonlinear disposition of the drug, a single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases. The effects of age upon the metabolism of fluoxetine have been investigated in 260 elderly but otherwise healthy depressed patients (≥60 years of age) who received 20 mg fluoxetine for 6 weeks. Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3 ± 85.7 ng/mL at the end of 6 weeks. No unusual age-associated pattern of adverse reactions was observed in those elderly patients.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span>— The pharmacokinetics of olanzapine and fluoxetine HCl has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. However, olanzapine and fluoxetine individual pharmacokinetics do not differ significantly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Olanzapine and fluoxetine HCl dosing adjustment based upon <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not routinely required.</p>
<p>Because olanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine. The pharmacokinetic characteristics of olanzapine were similar in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and normal subjects, indicating that dosage adjustment based upon the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not required. In addition, olanzapine is not removed by dialysis. The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on olanzapine metabolite elimination has not been studied.</p>
<p>In depressed patients on dialysis (N=12), fluoxetine administered as 20 mg once daily for 2 months produced steady state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in patients with normal renal function. While the possibility exists that renally excreted metabolites of fluoxetine may accumulate to higher levels in patients with severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span>— Based on the individual pharmacokinetic profiles of olanzapine and fluoxetine, the pharmacokinetics of olanzapine and fluoxetine HCl may be altered in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The lowest starting dose should be considered for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>) and Warnings and Precautions (<a href="#inv-dcf51e09-887d-44e2-aefc-a33f024fceb4">5.19</a>)]</span>. </p>
<p>Although the presence of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be expected to reduce the clearance of olanzapine, a study of the effect of <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> in subjects (N=6) with clinically significant cirrhosis (Childs-Pugh Classification A and B) revealed little effect on the pharmacokinetics of olanzapine.</p>
<p>As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of fluoxetine. The elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of 7.6 days compared with the range of 2 to 3 days seen in subjects without liver disease; norfluoxetine elimination was also delayed, with a mean duration of 12 days for cirrhotic patients compared with the range of 7 to 9 days in normal subjects.</p>
<p><span class="Underline">Gender </span>— Clearance of olanzapine is approximately 30% lower in women than in men. There were, however, no apparent differences between men and women in effectiveness or adverse effects. Dosage modifications based on gender should not be needed. </p>
<p><span class="Underline">Smoking Status </span>— Olanzapine clearance is about 40% higher in smokers than in <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span>, although dosage modifications are not routinely required. </p>
<p><span class="Underline">Race </span>— No olanzapine and fluoxetine HCl pharmacokinetic study was conducted to investigate the effects of race. <span class="Italics">In vivo</span> studies have shown that exposures to olanzapine are similar among Japanese, Chinese and Caucasians, especially after normalization for body weight differences. Dosage modifications for race, therefore, are not routinely required. </p>
<p><span class="Underline">Combined Effects </span>— The combined effects of age, smoking, and gender could lead to substantial pharmacokinetic differences in populations. The clearance of olanzapine in young smoking males, for example, may be 3 times higher than that in elderly nonsmoking females. Olanzapine and fluoxetine HCl dosing modification may be necessary in patients who exhibit a combination of factors that may result in slower metabolism of the olanzapine component <span class="Italics">[see Dosage and Administration (<a href="#inv-1231bce1-bec5-4dc5-84da-2a30d42ac454">2.3</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="inv-a43df4be-7591-48e2-a2f5-8a14f2954802"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY </h1>
<div class="Section" data-sectionCode="34083-6">
<a name="inv-5f98797a-89d1-49d2-b8c6-a25b5dfbf11d"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </h2>
<p class="First">No carcinogenicity, mutagenicity, or fertility studies were conducted with olanzapine and fluoxetine. The following data are based on findings in studies performed with the individual components, therefore all dose multiples (based on body surface area) reflect the maxium recommended human dose (MRHD) of 20 mg olanzapine, or 80 mg fluoxetine, when each drug is administered separately.</p>
<p><span class="Underline">Carcinogenesis </span></p>
<p><span class="Bold">Olanzapine </span>— Oral carcinogenicity studies were conducted in mice and rats. Olanzapine was administered to mice in two 78-week studies at doses of 3, 10, and 30/20 mg/kg/day [equivalent to 0.8 to 5 times the maximum recommended human daily dose (MRHD) on a mg/m<span class="Sup">2 </span>basis] and 0.25, 2, and 8 mg/kg/day (equivalent to 0.06 to 2 times the MRHD on a mg/m<span class="Sup">2 </span>basis). Rats were dosed for 2 years at doses of 0.25, 1, 2.5, and 4 mg/kg/day (males) and 0.25, 1, 4, and 8 mg/kg/day (females) (equivalent to 0.1 to 2 and 0.1 to 4 times the MRHD on a mg/m<span class="Sup">2 </span>basis, respectively). The incidence of liver <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span> was significantly increased in 1 mouse study in females dosed at 8 mg/kg/day (2 times the MRHD on a mg/m<span class="Sup">2 </span>basis). These tumors were not increased in another mouse study in females dosed at 10 or 30/20 mg/kg/day (2 to 5 times the MRHD on a mg/m<span class="Sup">2</span> basis); in this study, there was a high incidence of early mortalities in males of the 30/20 mg/kg/day group. The incidence of mammary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and adenocarcinomas was significantly increased in female mice dosed at ≥2 mg/kg/day and in female rats dosed at ≥4 mg/kg/day (0.5 and 2 times the MRHD on a mg/m<span class="Sup">2</span> basis, respectively). Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Serum prolactin levels were not measured during the olanzapine carcinogenicity studies; however, measurements during subchronic toxicity studies showed that olanzapine elevated serum prolactin levels up to 4-fold in rats at the same doses used in the carcinogenicity study. An increase in mammary gland neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin-mediated. The relevance for human risk of the finding of prolactin-mediated endocrine tumors in rodents is unknown <span class="Italics">[see Warnings and Precautions (<a href="#inv-4a8ae178-fcff-4c9f-b980-1c8db7209182">5.20</a>)]</span>. </p>
<p><span class="Bold">Fluoxetine </span>— The dietary administration of fluoxetine to rats and mice for 2 years at doses of up to 10 and 12 mg/kg/day, respectively (approximately 1.2 and 0.7 times, respectively, the MRHD on a mg/m<span class="Sup">2 </span>basis), produced no evidence of carcinogenicity. </p>
<p><span class="Underline">Mutagenesis </span></p>
<p><span class="Bold">Olanzapine </span>— No evidence of genotoxic potential for olanzapine was found in the Ames reverse mutation test, <span class="Italics">in vivo </span>micronucleus test in mice, the chromosomal aberration test in Chinese hamster ovary cells, unscheduled DNA synthesis test in rat hepatocytes, induction of forward mutation test in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, or <span class="Italics">in vivo</span> sister chromatid exchange test in bone marrow of Chinese hamsters. </p>
<p><span class="Bold">Fluoxetine </span>— Fluoxetine and norfluoxetine have been shown to have no genotoxic effects based on the following assays: bacterial mutation assay, DNA repair assay in cultured rat hepatocytes, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, and <span class="Italics">in vivo</span> sister chromatid exchange assay in Chinese hamster bone marrow cells. </p>
<p><span class="Underline">Impairment of Fertility </span></p>
<p><span class="Bold">Olanzapine and fluoxetine HCl</span> — Fertility studies were not conducted with olanzapine and fluoxetine HCl. However, in a repeat-dose rat toxicology study of 3 months duration, ovary weight was decreased in females treated with the low-dose [2 and 4 mg/kg/day (1 and 0.5 times the MRHD on a mg/ m<span class="Sup">2</span> basis), respectively] and high-dose [4 and 8 mg/kg/day (2 and 1 times the MRHD on a mg/m<span class="Sup">2</span> basis), respectively] combinations of olanzapine and fluoxetine. Decreased ovary weight, and corpora luteal depletion and uterine <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> were observed to a greater extent in the females receiving the high-dose combination than in females receiving either olanzapine or fluoxetine alone. In a 3-month repeat-dose dog toxicology study, reduced epididymal sperm and reduced testicular and prostate weights were observed with the high-dose combination of olanzapine and fluoxetine [5 and 5 mg/kg/day (9 and 2 times the MRHD on a mg/m<span class="Sup">2</span> basis), respectively] and with olanzapine alone (5 mg/kg/day or 9 times the MRHD on a mg/m<span class="Sup">2</span> basis). </p>
<p><span class="Bold">Olanzapine </span>— In an oral fertility and reproductive performance study in rats, male mating performance, but not fertility, was impaired at a dose of 22.4 mg/kg/day and female fertility was decreased at a dose of 3 mg/kg/day (11 and 1.5 times the MRHD on a mg/m<span class="Sup">2</span> basis, respectively). Discontinuance of olanzapine treatment reversed the effects on male-mating performance. In female rats, the precoital period was increased and the mating index reduced at 5 mg/kg/day (2.5 times the MRHD on a mg/m<span class="Sup">2</span> basis). Diestrous was prolonged and estrous was delayed at 1.1 mg/kg/day (0.6 times the MRHD on a mg/m<span class="Sup">2</span> basis); therefore, olanzapine may produce a delay in ovulation. </p>
<p><span class="Bold">Fluoxetine </span>— Two fertility studies conducted in adult rats at doses of up to 7.5 and 12.5 mg/kg/day (approximately 0.9 and 1.5 times the MRHD on a mg/m<span class="Sup">2</span> basis) indicated that fluoxetine had no adverse effects on fertility. However, adverse effects on fertility were seen when juvenile rats were treated with fluoxetine at a high dose (30 mg/kg) associated with significant toxicity <span class="Italics">[see Use in Specific Populations (<a href="#inv-a983ce35-3e93-4317-8735-fb289171fd06">8.4</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="inv-fd47beec-1a5e-4a8e-9440-2a8248c643b1"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-98a01770-83bd-4544-a927-5c835e23e7e2"></a><a name="section-14.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Episodes</span> Associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> </h2>
<p class="First">The efficacy of olanzapine and fluoxetine HCl for the acute treatment of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episodes</span> associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> was established in 2 identically designed, 8-week, randomized, double-blind, controlled studies of patients who met Diagnostic and Statistical Manual 4th edition (DSM-IV) criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>, Depressed utilizing flexible dosing of olanzapine and fluoxetine HCl (6/25 mg, 6/50 mg, or 12/50 mg/day), olanzapine (5 to 20 mg/day), and placebo. These studies included patients (≥18 years of age [n=788]) with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms and with or without a rapid cycling course.</p>
<p>The primary rating instrument used to assess <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> in these studies was the Montgomery-Asberg <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (MADRS), a 10-item clinician-rated scale with total scores ranging from 0 to 60. The primary outcome measure of these studies was the change from baseline to endpoint in the MADRS total score. In both studies, olanzapine and fluoxetine HCl was statistically significantly superior to both olanzapine monotherapy and placebo in reduction of the MADRS total score.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="inv-f1dedd6c-824f-433b-972f-3e2546b52a9d"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-f8a56c8b-6a85-4a53-9b2d-ea6cce36e6b9"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied </h2>
<p class="First">Olanzapine and fluoxetine capsules USP are supplied in 3/25 mg, 6/25 mg, 6/50 mg, 12/25 mg, and 12/50 mg (mg equivalent olanzapine/mg equivalent fluoxetine <span class="Sup">a</span>) strengths.</p>
<table>
<col width="23%">
<col width="21%">
<col width="18%">
<col width="18%">
<col width="18%">
<col width="18%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">
<span class="Sup">a</span> Fluoxetine base equivalent.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Olanzapine and Fluoxetine 	Capsules</span></p></td>
<td class="Toprule" align="center" colspan="5" valign="top"><p class="First"> CAPSULE STRENGTH</p></td>
</tr>
<tr>
<td valign="top"><p class="First"> 3 mg/25 mg</p></td>
<td valign="top"><p class="First"> 6 mg/25 mg</p></td>
<td valign="top"><p class="First"> 6 mg/50 mg</p></td>
<td valign="top"><p class="First"> 12 mg/25 mg</p></td>
<td valign="top"><p class="First"> 12 mg/50 mg</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Color</span></p></td>
<td valign="top"><p class="First"> white opaque body &amp; 	orange opaque cap</p></td>
<td valign="top"><p class="First"> rich yellow opaque body 	and cap</p></td>
<td valign="top"><p class="First"> light grey opaque body 	&amp; rich yellow opaque cap</p></td>
<td valign="top"><p class="First"> dark tan opaque body &amp; 	red opaque cap</p></td>
<td valign="top"><p class="First"> light grey opaque body 	&amp; red opaque cap</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Imprintings</span></p></td>
<td valign="top"><p class="First"> ‘277’ on body and ‘par’ on 	cap in black ink</p></td>
<td valign="top"><p class="First"> ‘par’ on body and ‘250’ on 	cap in black ink</p></td>
<td valign="top"><p class="First"> ‘251’ on body and ‘par’ on 	cap in black ink</p></td>
<td valign="top"><p class="First"> ‘252’ on body and ‘par’ on 	cap in black ink</p></td>
<td valign="top"><p class="First"> ‘253’ on body and ‘par’ on 	cap in black ink</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">NDC Codes</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First"> Bottle of 30</p></td>
<td valign="top"><p class="First"> 49884-277-11</p></td>
<td valign="top"><p class="First"> 49884-250-11</p></td>
<td valign="top"><p class="First"> 49884-251-11</p></td>
<td valign="top"><p class="First"> 49884-252-11</p></td>
<td valign="top"><p class="First"> 49884-253-11</p></td>
</tr>
<tr>
<td valign="top"><p class="First"> Bottle of 100</p></td>
<td valign="top"><p class="First"> 49884-277-01</p></td>
<td valign="top"><p class="First"> 49884-250-01</p></td>
<td valign="top"><p class="First"> 49884-251-01</p></td>
<td valign="top"><p class="First"> 49884-252-01</p></td>
<td valign="top"><p class="First"> 49884-253-01</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"> Bottle of 1000</p></td>
<td class="Botrule" valign="top"><p class="First"> 49884-277-10</p></td>
<td class="Botrule" valign="top"><p class="First"> 49884-250-10</p></td>
<td class="Botrule" valign="top"><p class="First"> 49884-251-10</p></td>
<td class="Botrule" valign="top"><p class="First"> 49884-252-10</p></td>
<td class="Botrule" valign="top"><p class="First"> 49884-253-10</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="inv-03075073-c663-4b4e-948b-c6b1267e97d3"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling </h2>
<p class="First">Store olanzapine and fluoxetine capsules at room temperature, between 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</p>
<p>Protect from light. Keep container tightly closed and protect from moisture.</p>
<p><span class="Sup">*</span> Zyprexa<span class="Sup">®</span>, Zyprexa Zydis<span class="Sup">®</span>, Prozac<span class="Sup">®</span>, Prozac Weekly<span class="Sup">™</span>, and Sarafem<span class="Sup">®</span> are registered trademarks of Eli Lilly and Company.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="inv-7e1444b4-0779-4076-8311-ff7309da97e9"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION </h1>
<p class="First"><span class="Italics">See FDA-approved Medication Guide. </span></p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking olanzapine and fluoxetine capsules.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-a49ec525-a8f6-4416-9aaa-4780e3122c70"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Information on Medication Guide </h2>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the potential benefits and potential risks associated with treatment with olanzapine and fluoxetine capsules and should counsel them in its appropriate use. A patient Medication Guide is available for olanzapine and fluoxetine capsules. The prescribers or other health professionals should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-ab2079cd-cd6f-4464-9a6e-8b636edf1a63"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk </h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#inv-889a889d-de41-4218-8626-2763d775e8d5">5.1</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-7dcfd413-3789-430c-978f-8a123fc0ea13"></a><a name="section-16.3"></a><p></p>
<h2>17.3 Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>: Increased Mortality and Cerebrovascular Adverse Events (CVAE), Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </h2>
<p class="First">Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with olanzapine had a significantly higher incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) compared with placebo. Olanzapine and fluoxetine capsules are not approved for elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see Boxed Warning and Warnings and Precautions (<a href="#inv-34dd836b-04ba-4a5e-8f5f-171da7c169b4">5.2</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-e74c3837-25db-4c1f-947c-c86ef7138fdd"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) </h2>
<p class="First">Patients and caregivers should be counseled that a potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including olanzapine, a component of olanzapine and fluoxetine. Signs and symptoms of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) <span class="Italics">[see Warnings and Precautions (<a href="#inv-7fe11f74-884b-4d48-9bfb-8dba19ebc1a0">5.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-5259af63-e319-46a8-9cc1-5f1125bd2e1f"></a><a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </h2>
<p class="First">Patients should be advised of the potential risk of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse reactions. Patients should be monitored regularly for worsening of glucose control. Patients and caregivers should be counseled that metabolic changes have occurred during treatment with olanzapine and fluoxetine HCl. Patients who have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> should follow their doctor's instructions about how often to check their blood sugar while taking olanzapine and fluoxetine capsules <span class="Italics">[see Warnings and Precautions (<a href="#inv-d8179809-2795-4eff-a8f1-796f6db0940a">5.4</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-668476de-d4ae-413c-8479-ee349dc2491c"></a><a name="section-16.6"></a><p></p>
<h2>17.6 <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">Hyperlipidemia</span> </h2>
<p class="First">Patients should be counseled that <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> has occurred during treatment with olanzapine and fluoxetine. Patients should have their lipid profile monitored regularly <span class="Italics">[see Warnings and Precautions (<a href="#inv-8bcdf333-e6c5-41cc-9c8a-bc83f4a66973">5.5</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8b6ac083-965e-4d3e-aee0-badc8a92a67c"></a><a name="section-16.7"></a><p></p>
<h2>17.7 <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> </h2>
<p class="First">Patients should be counseled that <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has occurred during treatment with olanzapine and fluoxetine. Patients should have their weight monitored regularly <span class="Italics">[see Warnings and Precautions (<a href="#inv-c82e5c02-0ff3-4459-bf36-bcc21c54d8a4">5.6</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-afca4010-a9a3-48ba-9001-2998e6db87d8"></a><a name="section-16.8"></a><p></p>
<h2>17.8 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> </h2>
<p class="First">Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of olanzapine and fluoxetine and other serotonergic agents including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John’s Wort <span class="Italics">[see Contraindications (4.1), Warnings and Precautions (<a href="#inv-944fa6b2-6ed2-4a0b-916d-7d0f46269a83">5.7</a>) and Drug Interactions (<a href="#inv-a9a74877-c887-49d1-aecc-75936155eb81">7.3</a>)]</span>. </p>
<p>Patients should be advised of the signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>  that may include metal status changes (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). Patients should be cautioned to seek medical care immediately if they experience these symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-8bba6d80-2a9b-4118-b023-3af6f1a5b303"></a><a name="section-16.9"></a><p></p>
<h2>17.9 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </h2>
<p class="First">Patients should be advised to notify their physician if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> <span class="Italics">[see Warnings and Precautions (<a href="#inv-f9bf1ec3-d4d7-4c6a-b32e-8857b18039a6">5.8</a>)]</span>. Patients should also be advised of the signs and symptoms associated with a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, eyes, or mouth, or have trouble breathing. Patients should be cautioned to seek medical care immediately if they experience these symptoms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-02172586-1d30-4027-9852-ee60361b0dd9"></a><a name="section-16.10"></a><p></p>
<h2>17.10 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during the period of initial dose titration and in association with the use of concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam or alcohol <span class="Italics">[see Warnings and Precautions (<a href="#inv-66597682-6f74-44e5-9c0e-69b9d506a574">5.11</a>) and Drug Interactions (</span><span class="Italics"><a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6,</a></span><span class="Italics"><a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. Patients should be advised to change positions carefully to help prevent <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and to lie down if they feel dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, until they feel better. Patients should be advised to call their doctor if they experience any of the following signs and symptoms associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, fast or slow heart beat, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-747ea154-3045-4e08-bebd-fe2649705581"></a><a name="section-16.11"></a><p></p>
<h2>17.11 Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> </h2>
<p class="First">Patients should be cautioned about the concomitant use of olanzapine and fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since the combined use of psychotropic drugs that interfere with serotonin reuptake and these agents have been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#inv-09cc51c9-342e-45cb-9784-0429d5c0b351">5.15</a>)]</span>. Patients should be advised to call their doctor if they experience any increased or unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking olanzapine and fluoxetine capsules. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-de88a31f-4d03-4e4e-a0de-1ecc86fe8439"></a><a name="section-16.12"></a><p></p>
<h2>17.12 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </h2>
<p class="First">Patients should be advised that <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> has been reported during treatment with SNRIs and SSRIs, including olanzapine and fluoxetine. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. More severe and/or acute cases have been associated with <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see Warnings and Precautions (<a href="#inv-9e6d3f5a-bb88-4467-af87-c86e9acdf898">5.16</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-73cc8ada-adee-4aac-b328-b8955309fab0"></a><a name="section-16.13"></a><p></p>
<h2>17.13 Potential for Cognitive and Motor Impairment </h2>
<p class="First">As with any CNS-active drug, olanzapine and fluoxetine has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that olanzapine and fluoxetine therapy does not affect them adversely <span class="Italics">[see Warnings and Precautions (<a href="#inv-3dee430c-291b-4312-8599-821fed557a6c">5.17</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-083a5da8-072a-46d1-b1cf-4bb9147dd70d"></a><a name="section-16.14"></a><p></p>
<h2>17.14 Body Temperature Regulation </h2>
<p class="First">Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Patients should be advised to call their doctor right away if they become severely ill and have some or all of these symptoms of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>: <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> too much or not at all, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, feeling very hot, feeling thirsty, not able to produce urine <span class="Italics">[see Warnings and Precautions (<a href="#inv-9fecc0ec-b6a9-411f-8be5-1dc51cf674db">5.18</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-dce874b2-74f4-4771-a1fb-a7c450fc9f2a"></a><a name="section-16.15"></a><p></p>
<h2>17.15 Concomitant Medication </h2>
<p class="First">Patients should be advised to inform their physician if they are taking Prozac, Prozac Weekly, Sarafem, fluoxetine, Zyprexa, or Zyprexa Zydis. Patients should be advised to inform their physicians if they are taking, plan to take, or have stopped taking any prescription or over-the-counter drugs, including herbal supplements, since there is a potential for interactions. Patients should also be advised to inform their physicians if they plan to discontinue any medications they are taking while taking olanzapine and fluoxetine capsules, as stopping a medication may also impact the overall blood level of olanzapine and fluoxetine <span class="Italics">[see Warnings and Precautions (<a href="#inv-8154c760-2029-477b-9842-13b1b0f2a067">5.21</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-38d728dd-23cc-44ee-a024-b2c50938a75c"></a><a name="section-16.16"></a><p></p>
<h2>17.16 Discontinuation of Treatment with Olanzapine and Fluoxetine HCl </h2>
<p class="First">Patients should be advised to take olanzapine and fluoxetine capsules exactly as prescribed, and to continue taking olanzapine and fluoxetine capsules as prescribed even after their mood symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking olanzapine and fluoxetine capsules, without consulting their physician <span class="Italics">[see Warnings and Precautions (<a href="#inv-9b672363-cf47-4954-99e9-869122a892c8">5.23</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-ef810992-91ba-4367-a1a2-5ea45ce33a98"></a><a name="section-16.17"></a><p></p>
<h2>17.17 Alcohol </h2>
<p class="First">Patients should be advised to avoid alcohol while taking olanzapine and fluoxetine capsules <span class="Italics">[see Drug Interactions (<a href="#inv-4d061a49-55e2-410b-b10e-760f9aa6656d">7.6</a><a href="#inv-09a34a53-9f2c-47d4-8f37-e515d5cd0c43">7.7</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-2e35c608-1041-4441-b429-5f3d6aaecf69"></a><a name="section-16.18"></a><p></p>
<h2>17.18 Use in Specific Populations </h2>
<p class="First"><span class="Underline">Pregnancy </span>-Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during olanzapine and fluoxetine therapy <span class="Italics">[see Use in Specific Populations (<a href="#inv-5a072cea-4133-49ad-b1d5-5efb495ce19f">8.1</a>)]</span>. </p>
<p><span class="Underline">Nursing Mothers </span>-Patients, if taking olanzapine and fluoxetine, should be advised not to breast-feed <span class="Italics">[see Use in Specific Populations (<a href="#inv-5a072cea-4133-49ad-b1d5-5efb495ce19f">8.1</a>)]</span>. </p>
<p>Manufactured by:</p>
<p><span class="Bold">Par Pharmaceutical Companies, Inc.</span></p>
<p><span class="Bold">Spring Valley, NY 10977</span></p>
<p>Revised: 03/2013</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="inv-97520243-c980-423b-9ff0-d4075f3d12a1"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First">Olanzapine and Fluoxetine Capsules USP</p>
<p>Read the Medication Guide that comes with olanzapine and fluoxetine capsules before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or you want to learn more about olanzapine and fluoxetine capsules.</p>
<p><span class="Bold">What is the most important information I should know about Olanzapine and Fluoxetine Capsules?</span></p>
<p><span class="Bold">Olanzapine and Fluoxetine Capsules may cause serious side effects, including:</span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold">Suicidal thoughts or actions.</span></dd>
<dt>2.</dt>
<dd><span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in elderly people who are <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, have <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span> and have lost touch with reality (<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>).</span></dd>
<dt>3.</dt>
<dd><span class="Bold">High blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>).</span></dd>
<dt>4.</dt>
<dd><span class="Bold">High fat levels in your blood (increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides), especially in teenagers age 13 to 17.</span></dd>
<dt>5.</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>, especially in teenagers age 13 to 17.</span></dd>
</dl>
<p><span class="Bold">These serious side effects are described below.</span></p>
<dl>
<dt>1.</dt>
<dd><span class="Bold">Suicidal thoughts or actions.</span></dd>
</dl>
<p><span class="Bold">Antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions</span>: </p>
<p><span class="Bold">Talk to your, or your family member's, healthcare provider about</span>: </p>
<dl>
<dt>•</dt>
<dd>all risks and benefits of treatment with antidepressant medicines.</dd>
<dt>•</dt>
<dd>all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness.<dl>
<dt>∘</dt>
<dd><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span></dd>
<dt>∘</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. </span>These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</dd>
<dt>∘</dt>
<dd><span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?</span></dd>
</dl>
</dd>
<dt>•</dt>
<dd>Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. </dd>
<dt>•</dt>
<dd>Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. </dd>
<dt>•</dt>
<dd>Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. </dd>
</dl>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<dl>
<dt>•</dt>
<dd>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying </dd>
<dt>•</dt>
<dd>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> </dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> </dd>
<dt>•</dt>
<dd>feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span> </dd>
<dt>•</dt>
<dd>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) </dd>
<dt>•</dt>
<dd>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> </dd>
<dt>•</dt>
<dd>acting aggressive, being angry, or violent </dd>
<dt>•</dt>
<dd>acting on dangerous impulses </dd>
<dt>•</dt>
<dd>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>) </dd>
<dt>•</dt>
<dd>or other unusual changes in behavior or mood. </dd>
</dl>
<p><span class="Bold">What else do I need to know about antidepressant medicines? </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider. </span>Stopping an antidepressant medicine suddenly can cause other symptoms.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses.</span> It is important to discuss all the risks of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.</dd>
<dt>•</dt>
<dd>
<span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your child's healthcare provider for more information. </dd>
</dl>
<p>2. <span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in elderly people who are <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, have memeory loss and have lost touch with reality (<span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>).</span> Olanzapine and fluoxetine capsules are not approved for treating <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> in elderly people with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</p>
<p>3. <span class="Bold">High blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>):</span> High blood sugar can happen if you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> already or if you have never had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. High blood sugar could lead to:</p>
<dl>
<dt>•</dt>
<dd>build up of acid in the blood due to <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> (<span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></dd>
</dl>
<p>Your doctor should do tests to check your blood sugar before you start taking olanzapine and fluoxetine capsules and during treatment. In people who do not have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, sometimes high blood sugar goes away when olanzapine and fluoxetine capsules are stopped. People with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and some people who did not have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> before taking olanzapine and fluoxetine hydrochloride need to take medicine for high blood sugar even after they stop taking olanzapine and fluoxetine capsules.</p>
<p>If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, follow your doctor's instructions about how often to check your blood sugar while taking olanzapine and fluoxetine capsules.</p>
<p><span class="Bold">Call your doctor </span>if you have any of these symptoms of high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) while taking olanzapine and fluoxetine capsules: </p>
<dl>
<dt>•</dt>
<dd>feel very thirsty </dd>
<dt>•</dt>
<dd>need to urinate more than usual </dd>
<dt>•</dt>
<dd>feel very hungry </dd>
<dt>•</dt>
<dd>feel weak or tired </dd>
<dt>•</dt>
<dd>feel sick to your stomach </dd>
<dt>•</dt>
<dd>feel <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span>, or your breath smells fruity. </dd>
</dl>
<p>4. <span class="Bold">High fat levels in your blood (increased <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides).</span> High fat levels may happen in people treated with olanzapine and fluoxetine capsules, especially in teenagers (13 to 17 years old) who received olanzapine, one of the drugs in olanzapine and fluoxetine capsules. Olanzapine and fluoxetine capsules are not approved for use in patients less than 18 years old. You may not have any symptoms, so your doctor should do blood tests to check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels before you start taking olanzapine and fluoxetine capsules and during treatment. </p>
<p>5. <span class="Bold">Increase in weight (<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>):</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> is common in people who take olanzapine and fluoxetine capsules. Teenagers (13 to 17 years old) who received olanzapine, one of the drugs in olanzapine and fluoxetine capsules, are more likely to gain weight and to gain more weight than adults. Olanzapine and fluoxetine capsules are not approved for use in people less than 18 years. Some people may gain a lot of weight while taking olanzapine and fluoxetine capsules, so you and your doctor should check your weight regularly. Talk to your doctor about ways to control <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, such as eating a healthy, balanced diet, and exercising. </p>
<p><span class="Bold">What is Olanzapine and Fluoxetine Capsules?</span></p>
<p>Olanzapine and fluoxetine capsules are a prescription medicine approved for use in adults:</p>
<dl>
<dt>•</dt>
<dd>for short-term treatment of episodes of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that happen with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>. </dd>
</dl>
<p>Olanzapine and fluoxetine capsules contain two medicines, olanzapine and fluoxetine hydrochloride.</p>
<p>It is not known if olanzapine and fluoxetine capsules are safe and effective in children under the age of 18.</p>
<p>The symptoms of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> include alternating periods of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and high or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> mood, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">increased activity</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4115026" conceptname="Racing thoughts">racing thoughts</span>, talking fast, <span class="product-label-link" type="condition" conceptid="4117518" conceptname="Impulsive character">impulsive behavior</span>, and a decreased need for sleep. With treatment, some of your symptoms of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> may improve.</p>
<p>If you do not think you are getting better, call your doctor.</p>
<p><span class="Bold">Who should not take Olanzapine and Fluoxetine Capsules? </span></p>
<dl>
<dt>•</dt>
<dd>Do not take olanzapine and fluoxetine capsules if you take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid. </dd>
<dt>•</dt>
<dd>Do not take an MAOI <span class="Bold">within 5 weeks of stopping olanzapine and fluoxetine unless directed to do so by your physician.</span>
</dd>
<dt>•</dt>
<dd>Do not start olanzapine and fluoxetine if you stopped taking and MAOI in the last 2 weeks unless directed to do so by your physician.</dd>
<dt> </dt>
<dd><span class="Bold"> People who take olanzapine and fluoxetine close in time to an MAOI can have serious and life-threatening side effects, with symptoms including:</span></dd>
<dt></dt>
<dd><dl>
<dt>∘</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
<dt>∘</dt>
<dd>continued <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> that you cannot control </dd>
<dt>∘</dt>
<dd>rigid muscles</dd>
<dt>∘</dt>
<dd>changes in heart rate and blood pressure that happen fast </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>. </dd>
</dl></dd>
<dt>•</dt>
<dd>Do not take olanzapine and fluoxetine capsules if you take Mellaril<span class="Sup">®</span> (thioridazine). Do not take Mellaril<span class="Sup">®</span><span class="Bold">within 5 weeks of stopping olanzapine and fluoxetine. Mellaril can cause serious heart rhythm problems and you could die suddenly.</span>
</dd>
<dt>•</dt>
<dd>Do not take olanzapine and fluoxetine capsules if you take the antipsychotic medicine pimozide (Orap<span class="Sup">®</span>). </dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking Olanzapine and Fluoxetine Capsules?</span></p>
<p>Olanzapine and fluoxetine capsules may not be right for you. Before starting olanzapine and fluoxetine capsules, tell your doctor about all your medical conditions, including if you have or had any of the following:</p>
<dl>
<dt>•</dt>
<dd>heart problems </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or high blood sugar levels (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) </dd>
<dt>•</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglyceride levels in your blood </dd>
<dt>•</dt>
<dd>liver problems </dd>
<dt>•</dt>
<dd>low or high blood pressure </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or “mini-strokes? also called <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems </dd>
<dt>•</dt>
<dd>Alzheimer's disease </dd>
<dt>•</dt>
<dd>narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> in men </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> </dd>
<dt>•</dt>
<dd>breast cancer </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if olanzapine and fluoxetine capsules will harm your unborn baby. </dd>
<dt>•</dt>
<dd>are breast-feeding or plan to breast-feed. Olanzapine and fluoxetine can pass into your breast milk and may harm your baby. You should not breast-feed while taking olanzapine and fluoxetine capsules. Talk to your doctor about the best way to feed your baby if you take olanzapine and fluoxetine capsules. </dd>
<dt> </dt>
<dd>Before starting olanzapine and fluoxetine capsules <span class="Bold">tell your doctor about all the medicines that you take, including</span>:</dd>
<dt>•</dt>
<dd>Prescription and non-prescription medicines</dd>
<dt>•</dt>
<dd>Vitamins, and herbal supplements</dd>
<dt>•</dt>
<dd>Triptans used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span></dd>
<dt>•</dt>
<dd>Medicines used to treat mood, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, buspirone, SSRIs, SNRIs, MAOIs, or antipsychotics</dd>
<dt>•</dt>
<dd>Tramadol and fentanyl</dd>
<dt>•</dt>
<dd>Over-the-counter supplements such as tryptophan or St. John’s Wort</dd>
<dt>•</dt>
<dd>Electroconvulsive therapy (ECT)</dd>
</dl>
<p>Olanzapine and fluoxetine and some medicines may interact with each other and may not work as well, or cause possible serious side effects. Your doctor can tell you if it is safe to take olanzapine and fluoxetine capsules with your other medicines. Do not start or stop any medicine while taking olanzapine and fluoxetine capsules without talking to your doctor first.</p>
<p><span class="Bold">If you take olanzapine and fluoxetine capsules, you should not take any other medicines that contain:</span></p>
<dl>
<dt>•</dt>
<dd>olanzapine (the active ingredient in Zyprexa<span class="Sup">®</span> and Zyprexa Zydis<span class="Sup">®</span>) or </dd>
<dt>•</dt>
<dd>fluoxetine hydrochloride (the active ingredient in Prozac<span class="Sup">®</span>, Prozac Weekly<span class="Sup">™</span>, and Sarafem<span class="Sup">®</span>).</dd>
</dl>
<p>You could take too much medicine (<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>).</p>
<p><span class="Bold">How should I take Olanzapine and Fluoxetine Capsules?</span></p>
<dl>
<dt>•</dt>
<dd>Take olanzapine and fluoxetine capsules exactly as prescribed. Your doctor may need to change (adjust) the dose of olanzapine and fluoxetine capsules until it is right for you. </dd>
<dt>•</dt>
<dd>If you miss a dose of olanzapine and fluoxetine capsules, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of olanzapine and fluoxetine capsules at the same time.</dd>
<dt>•</dt>
<dd><span class="Bold">To prevent serious side effects, do not stop taking Olanzapine and Fluoxetine Capsules suddenly. If you need to stop taking Olanzapine and Fluoxetine Capsules, your doctor can tell you how to safely stop taking it.</span></dd>
<dt>•</dt>
<dd><span class="Bold">If you take too much Olanzapine and Fluoxetine Capsules, call your doctor or poison control center right away, or get emergency treatment.</span></dd>
<dt>•</dt>
<dd>Olanzapine and fluoxetine capsules can be taken with or without food.</dd>
<dt>•</dt>
<dd>Olanzapine and fluoxetine capsules are usually taken one time each day, in the evening.</dd>
<dt>•</dt>
<dd>If you do not think you are getting better or have any concerns about your condition while taking olanzapine and fluoxetine capsules, call your doctor.</dd>
</dl>
<p><span class="Bold">What should I avoid while taking Olanzapine and Fluoxetine Capsules?</span></p>
<dl>
<dt>•</dt>
<dd>Olanzapine and fluoxetine capsules can cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> and may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how olanzapine and fluoxetine capsules affect you. </dd>
<dt>•</dt>
<dd>Avoid drinking alcohol while taking olanzapine and fluoxetine capsules. Drinking alcohol while you take olanzapine and fluoxetine capsules may make you sleepier than if you take olanzapine and fluoxetine capsules alone. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of Olanzapine and Fluoxetine Capsules?</span></p>
<p><span class="Bold">Other possible serious risks:</span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and increased incidence of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or “mini-strokes? called <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs) in elderly people with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> related to <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></span> (a brain disorder that lessens the ability to remember, think, and reason). Olanzapine and fluoxetine capsules are not approved for these patients. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>:</span> Tell your doctor right away if you get red <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">welts</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>) or, a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> alone or with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, while taking olanzapine and fluoxetine capsules. Call your doctor right away if you become severely ill and have some or all of these symptoms:<dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, or mouth</dd>
<dt>∘</dt>
<dd>trouble breathing</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> (NMS):</span> NMS is a rare but very serious condition that can happen in people who take antipsychotic medicines, including olanzapine and fluoxetine capsules. NMS can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in a hospital. Call your doctor right away if you become severely ill and have some or all of these symptoms:<dl>
<dt>∘</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
<dt>∘</dt>
<dd>excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </dd>
<dt>∘</dt>
<dd>rigid muscles </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>∘</dt>
<dd>changes in your breathing, heartbeat, and blood pressure </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:</span> This condition causes body movements that keep happening and that you cannot control. These movements usually affect the face and tongue. <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> may not go away, even if you stop taking olanzapine and fluoxetine capsules. It may also start after you stop taking olanzapine and fluoxetine capsules. Tell your doctor if you get any body movements that you cannot control. </dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>:</span> This is a condition that can be life threatening. Call your doctor right away if you become severely ill and have some or all of these symptoms:<dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or other changes in mental status</dd>
<dt>∘</dt>
<dd>coordination problems or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span> (overactive reflexes) </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span> </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> </dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span> Tell your doctor if you notice any increased or unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> while taking olanzapine and fluoxetine capsules, especially if you take one of these medicines:<dl>
<dt>∘</dt>
<dd>the blood thinner warfarin (Coumadin, Jantoven) </dd>
<dt>∘</dt>
<dd>a non-steroidal anti-inflammatory drug (NSAID) </dd>
<dt>∘</dt>
<dd>aspirin</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Low salt (sodium) levels in the blood (<span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>):</span> Call your doctor right away if you become severely ill and have some or all of these symptoms:<dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </dd>
<dt>∘</dt>
<dd>feel weak </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> </dd>
<dt>∘</dt>
<dd>problems concentrating </dd>
<dt>∘</dt>
<dd>memory problems </dd>
<dt>∘</dt>
<dd>feel unsteady </dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">Decreased blood pressure when you change positions, with symptoms of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, fast or slow heart beat, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">Difficulty swallowing</span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Problems with control of body temperature:</span> You could become very hot, for instance when you exercise a lot or stay in an area that is very hot. It is important for you to drink water to avoid <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. Call your doctor right away if you become severely ill and have some or all of these symptoms of <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>:<dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> too much or not at all </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> </dd>
<dt>∘</dt>
<dd>feeling very hot </dd>
<dt>∘</dt>
<dd>feeling thirsty </dd>
<dt>∘</dt>
<dd>not able to produce urine </dd>
</dl>
</dd>
</dl>
<p><span class="Bold">Common possible side effects of Olanzapine and Fluoxetine Capsules include: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, sleeping for long period of time, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your hands and feet, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> (shakes), or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>Tell your doctor about any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects with olanzapine and fluoxetine capsules. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Olanzapine and Fluoxetine Capsules?</span></p>
<dl>
<dt>•</dt>
<dd>Store olanzapine and fluoxetine capsules at room temperature, between 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F).</dd>
<dt>•</dt>
<dd>Keep olanzapine and fluoxetine capsules away from light. </dd>
<dt>•</dt>
<dd>Keep olanzapine and fluoxetine capsules dry and away from moisture. Keep the bottle closed tightly. </dd>
</dl>
<p><span class="Bold">Keep Olanzapine and Fluoxetine Capsules and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about Olanzapine and Fluoxetine Capsules</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use olanzapine and fluoxetine capsules for a condition for which it was not prescribed. Do not give olanzapine and fluoxetine capsules to other people, even if they have the same condition. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about olanzapine and fluoxetine capsules. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about olanzapine and fluoxetine capsules that was written for healthcare professionals.</p>
<p><span class="Bold">What are the ingredients in Olanzapine and Fluoxetine Capsules</span>?</p>
<p><span class="Bold">Active ingredients: </span>olanzapine and fluoxetine hydrochloride </p>
<p><span class="Bold">Inactive ingredients: </span>gelatin, magnesium stearate, partially pregelatinized starch, titanium dioxide, and yellow iron oxide. In addition, the 3 mg/25 mg capsule also contains red iron oxide; the 6 mg/50 mg capsule also contains FD&amp;C blue No. 2, FD&amp;C red No. 3, and FD&amp;C yellow No. 6; the 12 mg/25 mg capsule also contains D&amp;C red No. 28, FD&amp;C blue No. 1, FD&amp;C red No. 40, and red iron oxide; and the 12 mg/50 mg capsule also contains D&amp;C red No. 28, FD&amp;C blue No. 1 FD&amp;C blue No. 2, FD&amp;C red No. 3, FD&amp;C red No. 40, and FD&amp;C yellow No. 6. The capsules also have printing in edible black ink which contains the following ingredients: D&amp;C yellow No. 10, ethanol, FD&amp;C blue No. 1, FD&amp;C blue No. 2, FD&amp;C red No. 40, iron oxide black, methanol, n-Butyl alcohol, propylene glycol, and shellac glaze in alcohol. </p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration. </span></p>
<p>Revised 03/2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-aab35756-12a3-4158-b254-d35a7b6d93e6"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 100 CAPSULES</h1>
<div class="Figure">
<a name="ID0ELVBK"></a><img alt="100capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-a3e4b64e-a4a7-4230-9312-fc306782732b"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL –30 CAPSULES</h1>
<div class="Figure">
<a name="ID0ECWBK"></a><img alt="30capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-91163fe1-8c25-4102-8fed-ff13e48da479"></a><a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 1000 CAPSULES</h1>
<div class="Figure">
<a name="ID0EZWBK"></a><img alt="1000 capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-ab5e1063-66e2-4254-b6d3-9061852ba5a1"></a><a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 100 CAPSULES</h1>
<div class="Figure">
<a name="ID0EQXBK"></a><img alt="100capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="inv-64de989b-84ea-4586-b7f6-dd7e32ee1eaa"></a><a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 30 CAPSULES</h1>
<div class="Figure">
<a name="ID0EHYBK"></a><img alt="30capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d&amp;name=ea1113b0-50f1-4b4f-8e19-a7e066381de2-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINE AND FLUOXETINE 		
					</strong><br><span class="contentTableReg">olanzapine and fuoxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-277</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">3 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white opaque body) , orange (orange opaque cap) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">277;par</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-277-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-277-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:49884-277-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077742</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINE AND FLUOXETINE 		
					</strong><br><span class="contentTableReg">olanzapine and fuoxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">6 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (rich yellow opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">250;par</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-250-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-250-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:49884-250-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077742</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINE AND FLUOXETINE 		
					</strong><br><span class="contentTableReg">olanzapine and fuoxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-251</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">6 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (rich yellow opaque cap) , gray (light grey opaque body) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">251;par</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-251-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-251-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:49884-251-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077742</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINE AND FLUOXETINE 		
					</strong><br><span class="contentTableReg">olanzapine and fuoxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-252</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">12 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown (dark tan opaque body) , red (red opaque cap) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">252;par</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-252-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-252-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:49884-252-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077742</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>OLANZAPINE AND FLUOXETINE 		
					</strong><br><span class="contentTableReg">olanzapine and fuoxetine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49884-253</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OLANZAPINE</strong> (OLANZAPINE) </td>
<td class="formItem">OLANZAPINE</td>
<td class="formItem">12 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>FLUOXETINE HYDROCHLORIDE</strong> (FLUOXETINE) </td>
<td class="formItem">FLUOXETINE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 28</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 3</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">gray (light grey opaque body) , red (red opaque cap) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">253;par</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49884-253-11</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49884-253-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:49884-253-10</td>
<td class="formItem">1000  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077742</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Par Pharmaceutical, Inc
							(092733690)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Par Pharmaceutical, Inc. (092733690)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Par Pharmaceutical, Inc.</td>
<td class="formItem"></td>
<td class="formItem">092733690</td>
<td class="formItem">MANUFACTURE(49884-277, 49884-250, 49884-251, 49884-252, 49884-253)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ea1113b0-50f1-4b4f-8e19-a7e066381de2</div>
<div>Set id: 2f6ceda3-3edc-4427-98a6-23e3c930c44d</div>
<div>Version: 2</div>
<div>Effective Time: 20130227</div>
</div>
</div> <div class="DistributorName">Par Pharmaceutical, Inc</div></p>
</body></html>
